Skip Navigation

European Heart Journal 2001 22(20):1852-1923; doi:10.1053/euhj.2001.2983
Copyright © 2001 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Task Force Report

Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology

References

  1. Bellet S. Clinical Disorders of the Heart Beat. Philadelphia: Lea & Febiger; 1971.
  2. Prystowsky EN, Katz AM. Atrial fibrillation. Topol ES. Textbook of Cardiovascular Medicine. Philadelphia: Lippincott-Raven; 1998. p. 1827–1861
  3. Levy S, Breithardt G, Campbell RW. Atrial fibrillation: current knowledge and recommendations for management. Eur Heart J. 1998;19:1294–1320[Abstract/Free Full Text]
  4. Jais P, Haissaguerre M, Shah DC. A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation. 1997;95:572–576[Abstract/Free Full Text]
  5. Allessie MA, Konings KT, Kirchhof CJ. Mapping of atrial fibrillation. Olsson SB, Allessie MA, Campbell RW. Atrial Fibrillation: Mechanisms and Therapeutic Strategies. Armonk: Futura Publ; 1994. p. 37–49
  6. Levy S, Novella P, Ricard P, Paganelli F. Paroxysmal atrial fibrillation: a need for classification. J Cardiovasc Electrophysiol. 1995;6:69–74[Web of Science][Medline]
  7. Sopher SM, Camm AJ. Therapy for atrial fibrillation: control of the ventricular response and prevention of recurrence. Coron Artery Dis. 1995;6:106–114[Web of Science][Medline]
  8. Levy S. Classification system of atrial fibrillation. Curr Opin Cardiol. 2000;15:54–57[CrossRef][Web of Science][Medline]
  9. Gallagher MM, Camm J. Classification of atrial fibrillation. Am J Cardiol. 1998;82:18N–28N[CrossRef][Web of Science][Medline]
  10. Kopecky SL, Gersh BJ, McGoon MD. The natural history of lone atrial fibrillation: a population-based study over three decades. N Engl J Med. 1987;317:669–674[Abstract]
  11. Feinberg WM, Cornell ES, Nightingale SD. Relationship between prothrombin activation fragment F1.2 and international normalized ratio in patients with atrial fibrillation. Stroke. 1997;28:1101–1106[Abstract/Free Full Text]
  12. Ostranderld JR, Brandt RL, Kjelsberg MO, Epstein FH. Electrocardiographic findings among the adult population of a total natural community, Tecumseh, Michigan. Circulation. 1965;31:888–898[Abstract/Free Full Text]
  13. Flegel KM, Shipley MJ, Rose G. Risk of stroke in non-rheumatic atrial fibrillation [published erratum appears in Lancet 1987; 1: 878]. Lancet. 1987;1:526–529[CrossRef][Web of Science][Medline]
  14. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–988[Abstract/Free Full Text]
  15. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 1994;74:236–241[CrossRef][Web of Science][Medline]
  16. Kannel WB, Abbott RD, Savage DD, McNamara PM. Coronary heart disease and atrial fibrillation: the Framingham Study. Am Heart J. 1983;106:389–396[CrossRef][Web of Science][Medline]
  17. Psaty BM, Manolio TA, Kuller LH. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96:2455–2461[Abstract/Free Full Text]
  18. Go AS, Hylek EM, Phillips KA. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370–2375[Abstract/Free Full Text]
  19. Evans W, Swann P. Lone auricular fibrillation. Br Heart J. 1954;16:189–194[Medline]
  20. Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation: 30-year follow-up in the Framingham Study. JAMA. 1985;254:3449–3453[Abstract/Free Full Text]
  21. Levy S, Maarek M, Coumel P. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. Circulation. 1999;99:3028–3035[Abstract/Free Full Text]
  22. Murgatroyd FD, Gibson SM, Baiyan X. Double-blind placebo-controlled trial of digoxin in symptomatic paroxysmal atrial fibrillation. Circulation. 1999;99:2765–2770[Abstract/Free Full Text]
  23. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med. 1987;147:1561–1564[Abstract/Free Full Text]
  24. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995;98:476–484[CrossRef][Web of Science][Medline]
  25. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA. 1994;271:840–844[Abstract/Free Full Text]
  26. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999;100:376–380[Abstract/Free Full Text]
  27. Crijns HJ, Tjeerdsma G, De Kam PJ. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J. 2000;21:1238–1245[Abstract/Free Full Text]
  28. Arch Intern Med. 1994;154:1449–1457[Abstract/Free Full Text]
  29. Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med. 1999;131:688–695[Abstract/Free Full Text]
  30. Feinberg WM, Seeger JF, Carmody RF, Anderson DC, Hart RG, Pearce LA. Epidemiologic features of asymptomatic cerebral infarction in patients with nonvalvular atrial fibrillation. Arch Intern Med. 1990;150:2340–2344[Abstract/Free Full Text]
  31. Kempster PA, Gerraty RP, Gates PC. Asymptomatic cerebral infarction in patients with chronic atrial fibrillation. Stroke. 1988;19:955–957[Abstract/Free Full Text]
  32. Circulation. 1991;84:527–539[Abstract/Free Full Text]
  33. Petersen P, Madsen EB, Brun B, Pedersen F, Gyldensted C, Boysen G. Silent cerebral infarction in chronic atrial fibrillation. Stroke. 1987;18:1098–1100[Abstract/Free Full Text]
  34. Wolf PA, Dawber TR, Thomas HE Jr., Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham Study. Neurology. 1978;28:973–977[Abstract/Free Full Text]
  35. Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN. The influence of atrial fibrillation on prognosis in mild to moderate heart failure: the V-HeFT Studies. Circulation. 1993;87:VI-102–10[Medline]
  36. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials: Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1998;32:695–703[Abstract/Free Full Text]
  37. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med. 1995;155:469–473[Abstract/Free Full Text]
  38. Bharti S, Lev M. Histology of the normal and diseased atrium. Falk RH, Podrid PJ. Atrial Fibrillation: Mechanism and Management. New York: Raven Press; 1992. p. 15–39
  39. Guiraudon CM, Ernst NM, Yee R, Lein GJ. The pathology of drug resistant lone atrial fibrillation in eleven surgically treated patients. Kingma JH, Van Hernel NM, Lie KI. Atrial Fibrillation: A Treatable Disease?. Dordrecht: Kluwer Academic Publ; 1992. p. 41–57
  40. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997;96:1180–1184[Abstract/Free Full Text]
  41. Dittrich HC, Pearce LA, Asinger RW. Left atrial diameter in nonvalvular atrial fibrillation: an echocardiographic study. Am Heart J. 1999;137:494–499[CrossRef][Web of Science][Medline]
  42. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation. 1999;100:87–95[Abstract/Free Full Text]
  43. Maixent JM, Paganelli F, Scaglione J, Levy S. Antibodies against myosin in sera of patients with idiopathic paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 1998;9:612–617[Web of Science][Medline]
  44. Moe GK, Abildskov JA. Atrial fibrillation as a self sustaining arrhythmia independent of focal discharge. Am Heart J. 1959;58:59–70[CrossRef][Web of Science][Medline]
  45. Rensma PL, Allessie MA, Lammers WJ, Bonke FI, Schalij MJ. Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ Res. 1988;62:395–410[Abstract/Free Full Text]
  46. Scherf D, Romano FJ, Terranova R. Experimental studies on auricular flutter and auricular fibrillation. Am Heart J. 1948;36:241[CrossRef][Web of Science][Medline]
  47. Scherf D, Schaffer AI, Blumfeld S. Mechanism of flutter and fibrillation. Arch Intern Med. 1953;91:241–251
  48. Haissaguerre M, Jais P, Shah DC. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339:659–666[Abstract/Free Full Text]
  49. Chen SA, Tai CT, Yu WC. Right atrial focal atrial fibrillation: electrophysiologic characteristics and radiofrequency catheter ablation. J Cardiovasc Electrophysiol. 1999;10:328–335[Web of Science][Medline]
  50. Spach MS, Barr RC, Jewett PH. Spread of excitation from the atrium into thoracic veins in human beings and dogs. Am J Cardiol. 1972;30:844–854[CrossRef][Web of Science][Medline]
  51. Nathan H, Eliakim M. The junction between the left atrium and the pulmonary veins: an anatomic study of human hearts. Circulation. 1966;34:412–422[Abstract/Free Full Text]
  52. Zipes DP, Knope RF. Electrical properties of the thoracic veins. Am J Cardiol. 1972;29:372–376[CrossRef][Web of Science][Medline]
  53. Cheung DW. Electrical activity of the pulmonary vein and its interaction with the right atrium in the guinea-pig. J Physiol (Lond). 1981;314:445–456[Abstract/Free Full Text]
  54. Cheung DW. Pulmonary vein as an ectopic focus in digitalis-induced arrhythmia. Nature. 1981;294:582–584[CrossRef][Medline]
  55. Paes DA, Bohm CM, de Paula CM, Paes DC. The cardiac muscle in the pulmonary vein of the rat: a morphological and electrophysiological study. J Morphol. 1975;145:409–433[CrossRef][Web of Science][Medline]
  56. Moe GK, Abildskov JA. Observations on the ventricular dysrhythmia associated with atrial fibrillation in the dog heart. Circ Res. 1964;4:447–460
  57. Allessie MA, Lammers WJ, Bonke FI, Hollen J. Experimental evaluation of Moe's multiple wavelet hypothesis of atrial fibrillation. Zipes DP, Jalife J. Cardiac Electrophysiology and Arrhythmias. New York: Grune & Stratton; 1985. p. 265–276
  58. Cox JL, Canavan TE, Schuessler RB. The surgical treatment of atrial fibrillation, II: intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. J Thorac Cardiovasc Surg. 1991;101:406–426[Abstract]
  59. Konings KT, Kirchhof CJ, Smeets JR, Wellens HJ, Penn OC, Allessie MA. High-density mapping of electrically induced atrial fibrillation in humans. Circulation. 1994;89:1665–1680[Abstract/Free Full Text]
  60. Skanes AC, Mandapati R, Berenfeld O, Davidenko JM, Jalife J. Spatiotemporal periodicity during atrial fibrillation in the isolated sheep heart. Circulation. 1998;98:1236–1248[Abstract/Free Full Text]
  61. Kumagai K, Khrestian C, Waldo AL. Simultaneous multisite mapping studies during induced atrial fibrillation in the sterile pericarditis model: insights into the mechanism of its maintenance. Circulation. 1997;95:511–521[Abstract/Free Full Text]
  62. Gray RA, Pertsov AM, Jalife J. Incomplete reentry and epicardial breakthrough patterns during atrial fibrillation in the sheep heart. Circulation. 1996;94:2649–2661[Abstract/Free Full Text]
  63. Dorostkar PC, Cheng J, Scheinman MM. Electroanatomical mapping and ablation of the substrate supporting intraatrial reentrant tachycardia after palliation for complex congenital heart disease. Pacing Clin Electrophysiol. 1998;21:1810–1819[CrossRef][Medline]
  64. Konings, KTS, Mapping of electrically induced atrial fibrillation in humans [thesis], University of Limberg, Maastricht, Netherlands, 1999
  65. Ricard P, Levy S, Trigano J. Prospective assessment of the minimum energy needed for external electrical cardioversion of atrial fibrillation. Am J Cardiol. 1997;79:815–816[CrossRef][Web of Science][Medline]
  66. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation. 1995;92:1954–1968[Abstract/Free Full Text]
  67. Attuel P, Pellerin D, Gaston J. Latent atrial vulnerability: new means of electrophysiologic investigations in paroxysmal atrial arrhythmias. Attuel P, Coumel P, Janse MJ. The Atrium in Health and Disease. Mount Kisco: Futura Publ; 1989. p. 81–94
  68. Franz MR, Karasik PL, Li C, Moubarak J, Chavez M. Electrical remodeling of the human atrium: similar effects in patients with chronic atrial fibrillation and atrial flutter. J Am Coll Cardiol. 1997;30:1785–1792[Abstract]
  69. Olsson SB, Cotoi S, Varnauskas E. Monophasic action potential and sinus rhythm stability after conversion of atrial fibrillation. Acta Med Scand. 1971;190:381–387[Web of Science][Medline]
  70. Yue L, Feng J, Gaspo R, Li GR, Wang Z, Nattel S. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res. 1997;81:512–525[Abstract/Free Full Text]
  71. Fareh S, Benardeau A, Thibault B, Nattel S. The T-type Ca(2+) channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia-induced atrial remodeling in dogs. Circulation. 1999;100:2191–2197[Abstract/Free Full Text]
  72. Tieleman RG, De Langen C, Van Gelder IC. Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation. 1997;95:1945–1953[Abstract/Free Full Text]
  73. Daoud EG, Marcovitz P, Knight BP. Short-term effect of atrial fibrillation on atrial contractile function in humans. Circulation. 1999;99:3024–3027[Abstract/Free Full Text]
  74. Elvan A, Wylie K, Zipes DP. Pacing-induced chronic atrial fibrillation impairs sinus node function in dogs: electrophysiological remodeling. Circulation. 1996;94:2953–2960[Abstract/Free Full Text]
  75. Manios EG, Kanoupakis EM, Mavrakis HE, Kallergis EM, Dermitzaki DN, Vardas PE. Sinus pacemaker function after cardioversion of chronic atrial fibrillation: is sinus node remodeling related with recurrence? J Cardiovasc Electrophysiol. 2001;12:800–806[CrossRef][Web of Science][Medline]
  76. White CW, Kerber RE, Weiss HR, Marcus ML. The effects of atrial fibrillation on atrial pressure-volume and flow relationships. Circ Res. 1982;51:205–215[Abstract/Free Full Text]
  77. Edwards BS, Zimmerman RS, Schwab TR, Heublein DM, Burnett JC Jr. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res. 1988;62:191–195[Abstract/Free Full Text]
  78. Spach MS. Nonuniform anisotropic cellular coupling as a basis for reentrant arrhythmias. DiMarco JP, Prystowsky EN. Atrial Arrhythmias: State of the Art. Armonk: Futura Publ; 1995. p. 123–147
  79. Misier AR, Opthof T, van Hemel NM. Increased dispersion of ‘refractoriness’ in patients with idiopathic paroxysmal atrial fibrillation. J Am Coll Cardiol. 1992;19:1531–1535[Abstract]
  80. Cosio FG, Palacios J, Vidal JM, Cocina EG, Gomez-Sanchez MA, Tamargo L. Electrophysiologic studies in atrial fibrillation: slow conduction of premature impulses: a possible manifestation of the background for reentry. Am J Cardiol. 1983;51:122–130[CrossRef][Web of Science][Medline]
  81. Cox JL, Boineau JP, Schuessler RB, Jaquiss RD, Lappas DG. Modification of the maze procedure for atrial flutter and atrial fibrillation, I: rationale and surgical results. J Thorac Cardiovasc Surg. 1995;110:473–484[Abstract/Free Full Text]
  82. Cox JL, Jaquiss RD, Schuessler RB, Boineau JP. Modification of the maze procedure for atrial flutter and atrial fibrillation, II: surgical technique of the maze III procedure. J Thorac Cardiovasc Surg. 1995;110:485–495[Abstract/Free Full Text]
  83. Elvan A, Pride HP, Eble JN, Zipes DP. Radiofrequency catheter ablation of the atria reduces inducibility and duration of atrial fibrillation in dogs. Circulation. 1995;91:2235–2244[Abstract/Free Full Text]
  84. Klingenheben T, Gronefeld G, Li YG, Hohnloser SH. Heart rate variability to assess changes in cardiac vagal modulation prior to the onset of paroxysmal atrial fibrillation in patients with and without structural heart disease. ANE. 1999;4:19–26
  85. Chen SA, Hsieh MH, Tai CT. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation. 1999;100:1879–1886[Abstract/Free Full Text]
  86. Coumel P, Attuel P, Leclercq JF, Friocourt P. Atrial arrhythmias of vagal or catecholaminergic origin: comparative effects of beta-blocker treatment and the escape phenomenon [in French]. Arch Mal Coeur Vaiss. 1982;75:373–387[Web of Science][Medline]
  87. Prystowsky EN. Tachycardia-induced tachycardia: a mechanism of initiation of atrial fibrillation. DiMarco JP, Prystowsky EN. Atrial Arrhythmias: State of the Art. Armonk: Futura Publ; 1995. p. 123–149
  88. Hurwitz JL, German LD, Packer DL. Occurrence of atrial fibrillation in patients with paroxysmal supraventricular tachycardia due to atrioventricular nodal reentry. Pacing Clin Electrophysiol. 1990;13:705–710[CrossRef][Medline]
  89. Brugada J, Mont L, Matas M, Navarro-Lopez F. Atrial fibrillation induced by atrioventricular nodal reentrant tachycardia. Am J Cardiol. 1997;79:681–682[CrossRef][Web of Science][Medline]
  90. Prystowsky EN. Atrioventricular node reentry: physiology and radiofrequency ablation. Pacing Clin Electrophysiol. 1997;20:552–571[CrossRef][Medline]
  91. Mazgalev T, Dreifus LS, Bianchi J, Michelson EL. Atrioventricular nodal conduction during atrial fibrillation in rabbit heart. Am J Physiol. 1982;243:H754–60[Web of Science][Medline]
  92. Page RL, Wharton JM, Prystowsky EN. Effect of continuous vagal enhancement on concealed conduction and refractoriness within the atrioventricular node. Am J Cardiol. 1996;77:260–265[CrossRef][Web of Science][Medline]
  93. Lagendorf R, Pick AL, Katz LN. Ventricular response in atrial fibrillation: role of concealed conduction in the AV junction. Circulation. 1965;32:69–75[Abstract/Free Full Text]
  94. Page RL, Tang AS, Prystowsky EN. Effect of continuous enhanced vagal tone on atrioventricular nodal and sinoatrial nodal function in humans. Circ Res. 1991;68:1614–1620[Abstract/Free Full Text]
  95. Van Den Berg MP, Crijns HJ, Haaksma J, Brouwer J, Lie KI. Analysis of vagal effects on ventricular rhythm in patients with atrial fibrillation. Clin Sci (Colch). 1994;86:531–535[Medline]
  96. Gouaux JL, Ashman R. Auricular fibrillation with aberration simulating ventricular paroxysmal tachycardia. Am Heart J. 1947;34:366–373[CrossRef][Web of Science]
  97. Klein GJ, Bashore TM, Sellers TD, Pritchett EL, Smith WM, Gallagher JJ. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med. 1979;301:1080–1085[Abstract]
  98. Chen PS, Prystowsky EN. Role of concealed and supernormal conductions during atrial fibrillation in the preexcitation syndrome. Am J Cardiol. 1991;68:1329–1334[CrossRef][Web of Science][Medline]
  99. Dreifus LS, Haiat R, Watanabe Y, Arriaga J, Reitman N. Ventricular fibrillation: a possible mechanism of sudden death in patients and Wolff-Parkinson-White syndrome. Circulation. 1971;43:520–527[Abstract/Free Full Text]
  100. Prystowsky EN, Benson DW Jr., Fuster V. Management of patients with atrial fibrillation: a statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation. 1996;93:1262–1277[Free Full Text]
  101. Naito M, David D, Michelson EL, Schaffenburg M, Dreifus LS. The hemodynamic consequences of cardiac arrhythmias: evaluation of the relative roles of abnormal atrioventricular sequencing, irregularity of ventricular rhythm and atrial fibrillation in a canine model. Am Heart J. 1983;106:284–291[CrossRef][Web of Science][Medline]
  102. Clark DM, Plumb VJ, Epstein AE, Kay GN. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol. 1997;30:1039–1045[Abstract]
  103. Brookes CI, White PA, Staples M. Myocardial contractility is not constant during spontaneous atrial fibrillation in patients. Circulation. 1998;98:1762–1768[Abstract/Free Full Text]
  104. Upshaw CB Jr. Hemodynamic changes after cardioversion of chronic atrial fibrillation. Arch Intern Med. 1997;157:1070–1076[Abstract/Free Full Text]
  105. Van Den Berg MP, Tuinenburg AE, van Veldhuisen DJ, De Kam PJ, Crijns HJ. Cardioversion of atrial fibrillation in the setting of mild to moderate heart failure. Int J Cardiol. 1998;63:63–70[CrossRef][Web of Science][Medline]
  106. Morillo CA, Klein GJ, Jones DL, Guiraudon CM. Chronic rapid atrial pacing: structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation. 1995;91:1588–1595[Abstract/Free Full Text]
  107. Ausma J, Wijffels M, Thone F, Wouters L, Allessie M, Borgers M. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation. 1997;96:3157–3163[Abstract/Free Full Text]
  108. Sanfilippo AJ, Abascal VM, Sheehan M. Atrial enlargement as a consequence of atrial fibrillation: a prospective echocardiographic study. Circulation. 1990;82:792–797[Abstract/Free Full Text]
  109. Gosselink AT, Crijns HJ, Hamer HP, Hillege H, Lie KI. Changes in left and right atrial size after cardioversion of atrial fibrillation: role of mitral valve disease. J Am Coll Cardiol. 1993;22:1666–1672[Abstract]
  110. Mitusch R, Garbe M, Schmucker G, Schwabe K, Stierle U, Sheikhzadeh A. Relation of left atrial appendage function to the duration and reversibility of nonvalvular atrial fibrillation. Am J Cardiol. 1995;75:944–947[CrossRef][Web of Science][Medline]
  111. Manning WJ, Silverman DI, Katz SE. Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. J Am Coll Cardiol. 1994;23:1535–1540[Abstract]
  112. Packer DL, Bardy GH, Worley SJ. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol. 1986;57:563–570[CrossRef][Web of Science][Medline]
  113. Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol. 1992;69:1570–1573[CrossRef][Web of Science][Medline]
  114. Philips E, Levine SA. Auricular fibrillation without other evidence of heart disease: a cause of reversible heart failure. Am J Med. 1949;7:478–489[CrossRef][Web of Science][Medline]
  115. Kieny JR, Sacrez A, Facello A. Increase in radionuclide left ventricular ejection fraction after cardioversion of chronic atrial fibrillation in idiopathic dilated cardiomyopathy. Eur Heart J. 1992;13:1290–1295[Abstract/Free Full Text]
  116. Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinman MM. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol. 1997;29:709–715[Abstract]
  117. Halperin JL, Hart RG. Atrial fibrillation and stroke: new ideas, persisting dilemmas. Stroke. 1988;19:937–941[Free Full Text]
  118. Bogousslavsky J, Van Melle G, Regli F, Kappenberger L. Pathogenesis of anterior circulation stroke in patients with nonvalvular atrial fibrillation: the Lausanne Stroke Registry. Neurology. 1990;40:1046–1050[Abstract/Free Full Text]
  119. Miller VT, Rothrock JF, Pearce LA, Feinberg WM, Hart RG, Anderson DC. Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Neurology. 1993;43:32–36[Abstract/Free Full Text]
  120. Kanter MC, Tegeler CH, Pearce LA. Carotid stenosis in patients with atrial fibrillation: prevalence, risk factors, and relationship to stroke in the Stroke Prevention in Atrial Fibrillation Study. Arch Intern Med. 1994;154:1372–1377[Abstract/Free Full Text]
  121. Aschenberg W, Schluter M, Kremer P, Schroder E, Siglow V, Bleifeld W. Transesophageal two-dimensional echocardiography for the detection of left atrial appendage thrombus. J Am Coll Cardiol. 1986;7:163–166[Abstract]
  122. Mugge A, Kuhn H, Nikutta P, Grote J, Lopez JA, Daniel WG. Assessment of left atrial appendage function by biplane transesophageal echocardiography in patients with nonrheumatic atrial fibrillation: identification of a subgroup of patients at increased embolic risk. J Am Coll Cardiol. 1994;23:599–607[Abstract]
  123. Chimowitz MI, DeGeorgia MA, Poole RM, Hepner A, Armstrong WM. Left atrial spontaneous echo contrast is highly associated with previous stroke in patients with atrial fibrillation or mitral stenosis. Stroke. 1993;24:1015–1019[Abstract/Free Full Text]
  124. Manning WJ, Leeman DE, Gotch PJ, Come PC. Pulsed Doppler evaluation of atrial mechanical function after electrical cardioversion of atrial fibrillation. J Am Coll Cardiol. 1989;13:617–623[Abstract]
  125. Grimm RA, Stewart WJ, Maloney JD. Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: characterization by simultaneous transesophageal echocardiography. J Am Coll Cardiol. 1993;22:1359–1366[Abstract]
  126. Fatkin D, Kelly RP, Feneley MP. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. J Am Coll Cardiol. 1994;23:961–969[Abstract]
  127. Daniel WG, Nellessen U, Schroder E. Left atrial spontaneous echo contrast in mitral valve disease: an indicator for an increased thromboembolic risk. J Am Coll Cardiol. 1988;11:1204–1211[Abstract]
  128. Hwang JJ, Ko FN, Li YH. Clinical implications and factors related to left atrial spontaneous echo contrast in chronic nonvalvular atrial fibrillation. Cardiology. 1994;85:69–75[Web of Science][Medline]
  129. Pop GA, Meeder HJ, Roelandt JR. Transthoracic echo/Doppler in the identification of patients with chronic non-valvular atrial fibrillation at risk for thromboembolic events. Eur Heart J. 1994;15:1545–1551[Abstract/Free Full Text]
  130. Li YH, Lai LP, Shyu KG, Hwang JJ, Kuan P, Lien WP. Clinical implications of left atrial appendage flow patterns in nonrheumatic atrial fibrillation. Chest. 1994;105:748–752[CrossRef][Web of Science][Medline]
  131. Mitusch R, Lange V, Stierle U, Maurer B, Sheikhzadeh A. Transesophageal echocardiographic determinants of embolism in nonrheumatic atrial fibrillation. Int J Card Imaging. 1995;11:27–34[Web of Science][Medline]
  132. Black IW, Chesterman CN, Hopkins AP, Lee LC, Chong BH, Walsh WF. Hematologic correlates of left atrial spontaneous echo contrast and thromboembolism in nonvalvular atrial fibrillation. J Am Coll Cardiol. 1993;21:451–457[Abstract]
  133. Stoddard MF, Dawkins PR, Prince CR, Ammash NM. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J Am Coll Cardiol. 1995;25:452–459[Abstract]
  134. Manning WJ, Silverman DI, Waksmonski CA, Oettgen P, Douglas PS. Prevalence of residual left atrial thrombi among patients with acute thromboembolism and newly recognized atrial fibrillation. Arch Intern Med. 1995;155:2193–2198[Abstract/Free Full Text]
  135. Gustafsson C, Blomback M, Britton M, Hamsten A, Svensson J. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke. 1990;21:47–51[Abstract/Free Full Text]
  136. Heppell RM, Berkin KE, McLenachan JM, Davies JA. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart. 1997;77:407–411[Abstract/Free Full Text]
  137. Lip GY. Hypercoagulability and haemodynamic abnormalities in atrial fibrillation (comment). Heart. 1997;77:395–396[Free Full Text]
  138. Al-Saady NM, Davies MJ, Luddington LA. Tissue factor and von Willebrand factor expressions increased in the atrial tissue of the fibrillating atrium (Abstr). Circulation. 2000;100:I-285
  139. Mitusch R. Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy. Thromb Haemost. 1996;75:219–223[Web of Science][Medline]
  140. Lip GY, Lip PL, Zarifis J. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation: effects of introducing ultra-low-dose warfarin and aspirin. Circulation. 1996;94:425–431[Abstract/Free Full Text]
  141. Lip GY, Lowe GD, Rumley A, Dunn FG. Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis. Am Heart J. 1996;131:724–730[CrossRef][Web of Science][Medline]
  142. Asakura H, Hifumi S, Jokaji H. Prothrombin fragment F1+2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in atrial fibrillation. Blood Coagul Fibrinolysis. 1992;3:469–473[Web of Science][Medline]
  143. Sohara H, Amitani S, Kurose M, Miyahara K. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol. 1997;29:106–112[Abstract]
  144. Oltrona L, Broccolino M, Merlini PA, Spinola A, Pezzano A, Mannucci PM. Activation of the hemostatic mechanism after pharmacological cardioversion of acute nonvalvular atrial fibrillation. Circulation. 1997;95:2003–2006[Abstract/Free Full Text]
  145. Yamamoto K, Ikeda U, Seino Y. Coagulation activity is increased in the left atrium of patients with mitral stenosis. J Am Coll Cardiol. 1995;25:107–112[Abstract]
  146. Peverill RE, Harper RW, Gelman J, Gan TE, Harris G, Smolich JJ. Determinants of increased regional left atrial coagulation activity in patients with mitral stenosis. Circulation. 1996;94:331–339[Abstract/Free Full Text]
  147. Fukazawa H, Yamamoto K, Ikeda U, Shimada K. Effect of mitral regurgitation on coagulation activity in atrial fibrillation. Am J Cardiol. 1998;81:93–96[CrossRef][Web of Science][Medline]
  148. Asinger RW, Koehler J, Pearce LA. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation, II: dense spontaneous echocardiographic contrast (The Stroke Prevention in Atrial Fibrillation BRACESPAF-IIIBRACEO study). J Am Soc Echocardiogr. 1999;12:1088–1096[CrossRef][Web of Science][Medline]
  149. Goldman ME, Pearce LA, Hartz RG. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation, I: reduced flow velocity in the left atrial appendage. J Am Soc Echocardiogr. 2000;12:1080–1087[Web of Science]
  150. Blackshear JL, Pearce LA, Hart RG. Aortic plaque in atrial fibrillation: prevalence, predictors, and thromboembolic implications. Stroke. 1999;30:834–840[Abstract/Free Full Text]
  151. Collins LJ, Silverman DI, Douglas PS, Manning WJ. Cardioversion of nonrheumatic atrial fibrillation: reduced thromboembolic complications with 4 weeks of precardioversion anticoagulation are related to atrial thrombus resolution. Circulation. 1995;92:160–163[Abstract/Free Full Text]
  152. Hwang JJ, Shyu KG, Hsu KL, Chen JJ, Kuan P, Lien WP. Significant mitral regurgitation is protective against left atrial spontaneous echo contrast formation, but not against systemic embolism. Chest. 1994;106:8–12[CrossRef][Web of Science][Medline]
  153. Movsowitz C, Movsowitz HD, Jacobs LE, Meyerowitz CB, Podolsky LA, Kotler MN. Significant mitral regurgitation is protective against left atrial spontaneous echo contrast and thrombus as assessed by transesophageal echocardiography. J Am Soc Echocardiogr. 1993;6:107–114[Medline]
  154. Blackshear JL, Pearce LA, Asinger RW. Mitral regurgitation associated with reduced thromboembolic events in high-risk patients with nonrheumatic atrial fibrillation. Am J Cardiol. 1993;72:840–843[CrossRef][Web of Science][Medline]
  155. Hart RG, Pearce LA, Miller VT. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the Stroke Prevention in Atrial Fibrillation studies. Cerebrovasc Dis. 2000;10:39–43[CrossRef][Web of Science][Medline]
  156. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. J Am Coll Cardiol. 1998;31:1622–1626[Abstract/Free Full Text]
  157. Dreslinski GR, Frohlich ED, Dunn FG, Messerli FH, Suarez DH, Reisin E. Echocardiographic diastolic ventricular abnormality in hypertensive heart disease: atrial emptying index. Am J Cardiol. 1981;47:1087–1090[CrossRef][Web of Science][Medline]
  158. Frohlich ED, Apstein C, Chobanian AV. The heart in hypertension [published erratum appears in N Engl J Med 1992; 327: 1768]. N Engl J Med. 1992;327:998–1008[Web of Science][Medline]
  159. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA. 1996;275:1507–1513[Abstract/Free Full Text]
  160. Cushman M, Psaty BM, Macy E. Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease. Arterioscler Thromb Vasc Biol. 1996;16:1163–1169[Abstract/Free Full Text]
  161. Hursting MJ, Stead AG, Crout FV, Horvath BZ, Moore BM. Effects of age, race, sex, and smoking on prothrombin fragment 1.2 in a healthy population. Clin Chem. 1993;39:683–686[Abstract/Free Full Text]
  162. Lowe GD, Rumley A, Woodward M. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey, I: illustrative reference ranges by age, sex and hormone use. Br J Haematol. 1997;97:775–784[CrossRef][Web of Science][Medline]
  163. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. Stroke. 1999;30:1223–1229[Abstract/Free Full Text]
  164. J Stroke Cerebrovasc Dis. 1993;3:181–188
  165. Ann Intern Med. 1992;116:1–5[Abstract/Free Full Text]
  166. Ann Intern Med. 1992;116:6–12[Abstract/Free Full Text]
  167. Arch Intern Med. 1998;158:1316–1320[Abstract/Free Full Text]
  168. Yoshida M, Nakamura Y, Higashikawa M, Kinoshita M. Predictors of ischemic stroke in non-rheumatic atrial fibrillation. Int J Cardiol. 1996;56:61–70[CrossRef][Web of Science][Medline]
  169. Stollberger C, Chnupa P, Kronik G. Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation. Ann Intern Med. 1998;128:630–638[Abstract/Free Full Text]
  170. Tsai LM, Lin LJ, Teng JK, Chen JH. Prevalence and clinical significance of left atrial thrombus in nonrheumatic atrial fibrillation. Int J Cardiol. 1997;58:163–169[CrossRef][Web of Science][Medline]
  171. Rathore SS, Berger AK, Weinfurt KP. Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes. Circulation. 2000;101:969–974[Abstract/Free Full Text]
  172. Brugada R, Tapscott T, Czernuszewicz GZ. Identification of a genetic locus for familial atrial fibrillation. N Engl J Med. 1997;336:905–911[Abstract/Free Full Text]
  173. Coumel, P, Neural aspects of paroxysmal atrial fibrillation, Falk, RHPodrid, PJ, Atrial Fibrillation: Mechanisms and Management, New York, Raven Press, 1992, 109, 25
  174. Ganiats TG, Browner DK, Dittrich HC. Comparison of Quality of Well-Being scale and NYHA functional status classification in patients with atrial fibrillation: New York Heart Association. Am Heart J. 1998;135:819–824[CrossRef][Web of Science][Medline]
  175. Hamer ME, Blumenthal JA, McCarthy EA, Phillips BG, Pritchett EL. Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia. Am J Cardiol. 1994;74:826–829[CrossRef][Web of Science][Medline]
  176. Dorian P, Paquette M, Newman D, Green MS, Talajic M, Roy D. Quality of life improves following treatment in the Canadian Trial of Atrial Fibrillation (Abstr). Circulation. 1999;100:I-502
  177. Greenbaum RA. Oral dofetilide improves quality of life: an EMERALD substudy (Abstr). Circulation. 1999;100:I-493
  178. Am J Cardiol. 1997;79:1198–1202[CrossRef][Web of Science][Medline]
  179. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation: Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356:1789–1794[CrossRef][Web of Science][Medline]
  180. Marshall HJ, Harris ZI, Griffith MJ, Holder RL, Gammage MD. Prospective randomized study of ablation and pacing versus medical therapy for paroxysmal atrial fibrillation: effects of pacing mode and mode-switch algorithm. Circulation. 1999;99:1587–1592[Abstract/Free Full Text]
  181. Natale A, Zimerman L, Tomassoni G. AV node ablation and pacemaker implantation after withdrawal of effective rate-control medications for chronic atrial fibrillation: effect on quality of life and exercise performance. Pacing Clin Electrophysiol. 1999;22:1634–1639[CrossRef][Medline]
  182. Brignole M, Menozzi C, Gianfranchi L. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study. Circulation. 1998;98:953–960[Abstract/Free Full Text]
  183. Kay GN, Ellenbogen KA, Giudici M. The Ablate and Pace Trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. J Interv Card Electrophysiol. 1998;2:121–135[CrossRef][Web of Science][Medline]
  184. Marshall HJ, Harris ZI, Griffith MJ, Gammage MD. Atrioventricular nodal ablation and implantation of mode switching dual chamber pacemakers: effective treatment for drug refractory paroxysmal atrial fibrillation. Heart. 1998;79:543–547[Abstract/Free Full Text]
  185. Brignole M, Gianfranchi L, Menozzi C. Assessment of atrioventricular junction ablation and DDDR mode-switching pacemaker versus pharmacological treatment in patients with severely symptomatic paroxysmal atrial fibrillation: a randomized controlled study. Circulation. 1997;96:2617–2624[Abstract/Free Full Text]
  186. Bubien RS, Knotts-Dolson SM, Plumb VJ, Kay GN. Effect of radiofrequency catheter ablation on health-related quality of life and activities of daily living in patients with recurrent arrhythmias. Circulation. 1996;94:1585–1591[Abstract/Free Full Text]
  187. Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation. 2000;101:1138–1144[Abstract/Free Full Text]
  188. Anselme F, Saoudi N, Poty H, Douillet R, Cribier A. Radiofrequency catheter ablation of common atrial flutter: significance of palpitations and quality-of-life evaluation in patients with proven isthmus block. Circulation. 1999;99:534–540[Abstract/Free Full Text]
  189. Lee SH, Tai CT, Yu WC. Effects of radiofrequency catheter ablation on quality of life in patients with atrial flutter. Am J Cardiol. 1999;84:278–283[CrossRef][Web of Science][Medline]
  190. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 1996;156:1829–1836[Abstract/Free Full Text]
  191. Protheroe J, Fahey T, Montgomery AA, Peters TJ. The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. BMJ. 2000;320:1380–1384[Abstract/Free Full Text]
  192. Kerr CR, Boone J, Connolly SJ. The Canadian Registry of Atrial Fibrillation: a noninterventional follow-up of patients after the first diagnosis of atrial fibrillation. Am J Cardiol. 1998;82:82N–5N[CrossRef][Web of Science][Medline]
  193. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med. 1982;306:1018–1022[Abstract]
  194. Cuddy TE, Connolly SJ. Atrial fibrillation and atrial flutter. Can J Cardiol. 1996;12:9A–11A
  195. Manning WJ, Silverman DI, Gordon SP, Krumholz HM, Douglas PS. Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi. N Engl J Med. 1993;328:750–755[Abstract/Free Full Text]
  196. Krahn AD, Klein GJ, Kerr CR. How useful is thyroid function testing in patients with recent-onset atrial fibrillation? Arch Intern Med. 1996;156:2221–2224[Abstract/Free Full Text]
  197. Gillis AM, Klein GJ, MacDonald RG. Investigation of the patient with atrial fibrillation. Can J Cardiol. 1996;12:12A–13A[Medline]
  198. Seward JB, Khandheria BK, Freeman WK. Multiplane transesophageal echocardiography: image orientation, examination technique, anatomic correlations, and clinical applications. Mayo Clin Proc. 1993;68:523–551[Web of Science][Medline]
  199. Agmon Y, Khandheria BK, Gentile F, Seward JB. Echocardiographic assessment of the left atrial appendage. J Am Coll Cardiol. 1999;34:1867–1877[Abstract/Free Full Text]
  200. Pearson AC, Labovitz AJ, Tatineni S, Gomez CR. Superiority of transesophageal echocardiography in detecting cardiac source of embolism in patients with cerebral ischemia of uncertain etiology. J Am Coll Cardiol. 1991;17:66–72[Abstract]
  201. Klein AL, Grimm RA, Murray RD. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001;344:1411–1420[Abstract/Free Full Text]
  202. Leung DY, Black IW, Cranney GB, Hopkins AP, Walsh WF. Prognostic implications of left atrial spontaneous echo contrast in nonvalvular atrial fibrillation. J Am Coll Cardiol. 1994;24:755–762[Abstract]
  203. Manning WJ, Silverman DI, Keighley CS, Oettgen P, Douglas PS. Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study. J Am Coll Cardiol. 1995;25:1354–1361[Abstract]
  204. Klein AL, Grimm RA, Black IW. Cardioversion guided by transesophageal echocardiography: the ACUTE Pilot Study: a randomized, controlled trial: Assessment of Cardioversion Using Transesophageal Echocardiography. Ann Intern Med. 1997;126:200–209[Abstract/Free Full Text]
  205. Black IW, Fatkin D, Sagar KB. Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation: a multicenter study. Circulation. 1994;89:2509–2513[Abstract/Free Full Text]
  206. Borgeat A, Goy JJ, Maendly R, Kaufmann U, Grbic M, Sigwart U. Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol. 1986;58:496–498[CrossRef][Web of Science][Medline]
  207. Suttorp MJ, Kingma JH, Lie AH, Mast EG. Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol. 1989;63:693–696[CrossRef][Web of Science][Medline]
  208. Suttorp MJ, Kingma JH, Jessurun ER, Lie AH, van Hemel NM, Lie KI. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol. 1990;16:1722–1727[Abstract]
  209. Platia EV, Michelson EL, Porterfield JK, Das G. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol. 1989;63:925–929[CrossRef][Web of Science][Medline]
  210. Capucci A, Lenzi T, Boriani G. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol. 1992;70:69–72[CrossRef][Web of Science][Medline]
  211. Capucci A, Boriani G, Rubino I, Della CS, Sanguinetti M, Magnani B. A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm. Int J Cardiol. 1994;43:305–313[CrossRef][Web of Science][Medline]
  212. Azpitarte J, Alvarez M, Baun O. Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation: results of a randomized, double-blind, controlled study. Eur Heart J. 1997;18:1649–1654[Abstract/Free Full Text]
  213. Kochiadakis GE, Igoumenidis NE, Solomou MC, Kaleboubas MD, Chlouverakis GI, Vardas PE. Efficacy of amiodarone for the termination of persistent atrial fibrillation. Am J Cardiol. 1999;83:58–61[Web of Science][Medline]
  214. Galve E, Rius T, Ballester R. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol. 1996;27:1079–1082[Abstract]
  215. Falk RH, Pollak A, Singh SN, Friedrich T. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J Am Coll Cardiol. 1997;29:385–390[Abstract]
  216. Norgaard BL, Wachtell K, Christensen PD. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Am Heart J. 1999;137:1062–1069[CrossRef][Web of Science][Medline]
  217. Peuhkurinen K, Niemela M, Ylitalo A, Linnaluoto M, Lilja M, Juvonen J. Effectiveness of amiodarone as a single oral dose for recent-onset atrial fibrillation. Am J Cardiol. 2000;85:462–465[CrossRef][Web of Science][Medline]
  218. Kerin NZ, Faitel K, Naini M. The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation: amiodarone vs quinidine for conversion of atrial fibrillation. Arch Intern Med. 1996;156:49–53[Abstract/Free Full Text]
  219. Zehender M, Hohnloser S, Muller B, Meinertz T, Just H. Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up. J Am Coll Cardiol. 1992;19:1054–1059[Abstract]
  220. Donovan KD, Power BM, Hockings BE, Dobb GJ, Lee KY. Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am J Cardiol. 1995;75:693–697[CrossRef][Web of Science][Medline]
  221. Bertini G, Conti A, Fradella G. Propafenone versus amiodarone in field treatment of primary atrial tachydysrhythmias. J Emerg Med. 1990;8:15–20[CrossRef][Medline]
  222. Hou ZY, Chang MS, Chen CY. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone: a randomized, digoxin-controlled study. Eur Heart J. 1995;16:521–528[Abstract/Free Full Text]
  223. Opolski G, Stanislawska J, Gorecki A, Swiecicka G, Torbicki A, Kraska T. Amiodarone in restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation after unsuccessful direct-current cardioversion. Clin Cardiol. 1997;20:337–340[Web of Science][Medline]
  224. Noc M, Stajer D, Horvat M. Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm. Am J Cardiol. 1990;65:679–680[CrossRef][Web of Science][Medline]
  225. Tieleman RG, Gosselink AT, Crijns HJ. Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. Am J Cardiol. 1997;79:53–57[CrossRef][Web of Science][Medline]
  226. Sedgwick ML, Lip G, Rae AP, Cobbe SM. Chemical cardioversion of atrial fibrillation with intravenous dofetilide. Int J Cardiol. 1995;49:159–166[CrossRef][Web of Science][Medline]
  227. Torp-Pedersen C, Moller M, Bloch-Thomsen PE. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med. 1999;341:857–865[Abstract/Free Full Text]
  228. Lindeboom JE, Kingma JH, Crijns HJ, Dunselman PH. Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter. Am J Cardiol. 2000;85:1031–1033[CrossRef][Web of Science][Medline]
  229. Botto GL, Bonini W, Broffoni T. Regular ventricular rhythms before conversion of recent onset atrial fibrillation to sinus rhythm. Pacing Clin Electrophysiol. 1994;17:2114–2117[CrossRef][Medline]
  230. Botto GL, Capucci A, Bonini W. Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: comparison of two regimens. Int J Cardiol. 1997;58:55–61[CrossRef][Web of Science][Medline]
  231. Donovan KD, Dobb GJ, Coombs LJ. Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecainide. Am J Cardiol. 1991;67:137–141[CrossRef][Web of Science][Medline]
  232. Barranco F, Sanchez M, Rodriguez J, Guerrero M. Efficacy of flecainide in patients with supraventricular arrhythmias and respiratory insufficiency. Intensive Care Med. 1994;20:42–44[CrossRef][Web of Science][Medline]
  233. Baldi N, Russo VA, Lenti V. Relation between plasma levels and efficacy of flecainide and propafenone for treatment of atrial fibrillation of recent onset. New Trends Arrhythmias. 1993;9:899–906
  234. Stambler BS, Wood MA, Ellenbogen KA. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy. Circulation. 1997;96:4298–4306[Abstract/Free Full Text]
  235. Guo GB, Ellenbogen KA, Wood MA, Stambler BS. Conversion of atrial flutter by ibutilide is associated with increased atrial cycle length variability. J Am Coll Cardiol. 1996;27:1083–1089[Abstract]
  236. Volgman AS, Carberry PA, Stambler B. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol. 1998;31:1414–1419[Abstract/Free Full Text]
  237. Vos MA, Golitsyn SR, Stangl K. Superiority of ibutilide (a new class III agent) over dl-sotalol in converting atrial flutter and atrial fibrillation. Heart. 1998;79:568–575[Abstract/Free Full Text]
  238. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation. 1996;94:1613–1621[Abstract/Free Full Text]
  239. Ellenbogen KA, Stambler BS, Wood MA. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study [published erratum appears in J Am Coll Cardiol 1996; 28: 1082]. J Am Coll Cardiol. 1996;28:130–136[Abstract]
  240. Boriani G, Capucci A, Lenzi T, Sanguinetti M, Magnani B. Propafenone for conversion of recent-onset atrial fibrillation: a controlled comparison between oral loading dose and intravenous administration. Chest. 1995;108:355–358[CrossRef][Web of Science][Medline]
  241. Boriani G, Biffi M, Capucci A. Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease: a randomized, controlled trial. Ann Intern Med. 1997;126:621–625[Abstract/Free Full Text]
  242. Fresco C, Proclemer A, Pavan A. Intravenous propafenone in paroxysmal atrial fibrillation: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Clin Cardiol. 1996;19:409–412[Web of Science][Medline]
  243. Stroobandt R, Stiels B, Hoebrechts R. Propafenone for conversion and prophylaxis of atrial fibrillation. Am J Cardiol. 1997;79:418–423[CrossRef][Web of Science][Medline]
  244. Bellandi F, Cantini F, Pedone T, Palchetti R, Bamoshmoosh M, Dabizzi RP. Effectiveness of intravenous propafenone for conversion of recent-onset atrial fibrillation: a placebo-controlled study. Clin Cardiol. 1995;18:631–634[Web of Science][Medline]
  245. Bianconi L, Mennuni M, Lukic V, Castro A, Chieffi M, Santini M. Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. J Am Coll Cardiol. 1996;28:700–706[Abstract]
  246. Weiner P, Ganam R, Zidan F, Rabner M. Clinical course of recent-onset atrial fibrillation treated with oral propafenone. Chest. 1994;105:1013–1016[CrossRef][Web of Science][Medline]
  247. Di Benedetto S. Quinidine versus propafenone for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol. 1997;80:518–519[CrossRef][Web of Science][Medline]
  248. Vita JA, Friedman PL, Cantillon C, Antman EM. Efficacy of intravenous propafenone for the acute management of atrial fibrillation. Am J Cardiol. 1989;63:1275–1278[CrossRef][Web of Science][Medline]
  249. Barroffio R, Tisi G, Guzzini F, Milvio E, Annoni P. A randomised study comparing digoxin and propafenone in the treatment of recent onset atrial fibrillation. Clin Drug Invest. 1995;9:277–283
  250. Hohnloser SH, van de LA, Baedeker F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. J Am Coll Cardiol. 1995;26:852–858[Abstract]
  251. Halinen MO, Huttunen M, Paakkinen S, Tarssanen L. Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine Trial). Am J Cardiol. 1995;76:495–498[CrossRef][Web of Science][Medline]
  252. Pilati G, Lenzi T, Trisolino G. Amiodarone versus quinidine for conversion of recent onset atrial fibrillation to sinus rhythm. Curr Ther Res. 1991;49:140–146
  253. Sweany AE, Moncloa F, Vickers FF, Zupkis RV. Antiarrhythmic effects of intravenous timolol in supraventricular arrhythmias. Clin Pharmacol Ther. 1985;37:124–127[Web of Science][Medline]
  254. Boudonas G, Lefkos N, Efthymiadis AP, Styliadis IG, Tsapas G. Intravenous administration of diltiazem in the treatment of supraventricular tachyarrhythmias. Acta Cardiol. 1995;50:125–134[Web of Science][Medline]
  255. Falk RH, Knowlton AA, Bernard SA, Gotlieb NE, Battinelli NJ. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm: a randomized, double-blinded trial. Ann Intern Med. 1987;106:503–506[Abstract/Free Full Text]
  256. Singh S, Saini RK, DiMarco J, Kluger J, Gold R, Chen YW. Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation. Am J Cardiol. 1991;68:1227–1230[CrossRef][Web of Science][Medline]
  257. Jordaens L. Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo. Eur Heart J. 1997;18:643–648[Abstract/Free Full Text]
  258. Eur Heart J. 1997;18:649–654[Abstract/Free Full Text]
  259. Madrid AH, Moro C, Marin-Huerta E, Mestre JL, Novo L, Costa A. Comparison of flecainide and procainamide in cardioversion of atrial fibrillation. Eur Heart J. 1993;14:1127–1131[Abstract/Free Full Text]
  260. Sung RJ, Tan HL, Karagounis L. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Am Heart J. 1995;129:739–748[CrossRef][Web of Science][Medline]
  261. Singh S, Zoble RG, Yellen L. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study. Circulation. 2000;102:2385–2390[Abstract/Free Full Text]
  262. Vardas PE, Kochiadakis GE, Igoumenidis NE, Tsatsakis AM, Simantirakis EN, Chlouverakis GI. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. Chest. 2000;117:1538–1545[CrossRef][Web of Science][Medline]
  263. Hou CJ, Chang-Sing P, Flynn E. Determination of ventricular vulnerable period and ventricular fibrillation threshold by use of T-wave shocks in patients undergoing implantation of cardioverter/defibrillators. Circulation. 1995;92:2558–2564[Medline]
  264. Ewy GA. The optimal technique for electrical cardioversion of atrial fibrillation. Clin Cardiol. 1994;17:79–84[Web of Science][Medline]
  265. Dalzell GW, Cunningham SR, Anderson J, Adgey AA. Electrode pad size, transthoracic impedance and success of external ventricular defibrillation. Am J Cardiol. 1989;64:741–744[CrossRef][Web of Science][Medline]
  266. Connell PN, Ewy GA, Dahl CF, Ewy MD. Transthoracic impedance to defibrillator discharge: effect of electrode size and electrode-chest wall interface. J Electrocardiol. 1973;6:313–M[Web of Science][Medline]
  267. Kerber RE, Jensen SR, Grayzel J, Kennedy J, Hoyt R. Elective cardioversion: influence of paddle-electrode location and size on success rates and energy requirements. N Engl J Med. 1981;305:658–662[Abstract]
  268. Mittal S, Ayati S, Stein KM. Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks. Circulation. 2000;101:1282–1287[Abstract/Free Full Text]
  269. Lown B, Amarasingham R, Neuman J. New method for terminating cardiac arrhythmias: use of synchronized capacitor discharge. JAMA. 1962;182:548–555[Abstract/Free Full Text]
  270. Lown B, Perlroth MG, Kaidbey S, Abe T, Harken DE. Cardioversion of atrial fibrillation: a report on the treatment of 65 episodes in 50 patients. N Engl J Med. 1963;269:325–331[Web of Science][Medline]
  271. Kerber RE, Martins JB, Kienzle MG. Energy, current, and success in defibrillation and cardioversion: clinical studies using an automated impedance-based method of energy adjustment. Circulation. 1988;77:1038–1046[Abstract/Free Full Text]
  272. Crampton R. Accepted, controversial, and speculative aspects of ventricular defibrillation. Prog Cardiovasc Dis. 1980;23:167–186[CrossRef][Web of Science][Medline]
  273. Botto GL, Politi A, Bonini W, Broffoni T, Bonatti R. External cardioversion of atrial fibrillation: role of paddle position on technical efficacy and energy requirements. Heart. 1999;82:726–730[Abstract/Free Full Text]
  274. Lesser MF. Safety and efficacy of in-office cardioversion for treatment of supraventricular arrhythmias. Am J Cardiol. 1990;66:1267–1268[CrossRef][Web of Science][Medline]
  275. Dahl CF, Ewy GA, Warner ED, Thomas ED. Myocardial necrosis from direct current countershock: effect of paddle electrode size and time interval between discharges. Circulation. 1974;50:956–961[Abstract/Free Full Text]
  276. Joglar JA, Hamdan MH, Ramaswamy K. Initial energy for elective external cardioversion of persistent atrial fibrillation. Am J Cardiol. 2000;86:348–350[CrossRef][Web of Science][Medline]
  277. Van Gelder IC, Crijns HJ, van Gilst WH, Verwer R, Lie KI. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol. 1991;68:41–46[Web of Science][Medline]
  278. Sodermark T, Jonsson B, Olsson A. Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter: a multicentre study from Stockholm. Br Heart J. 1975;37:486–492[Abstract/Free Full Text]
  279. Lundstrom T, Ryden L. Chronic atrial fibrillation: long-term results of direct current conversion. Acta Med Scand. 1988;223:53–59[Web of Science][Medline]
  280. Cramer G. Early and late results of conversion of atrial fibrillation with quinidine: a clinical and hemodynamic study. Acta Med Scand Suppl. 1968;490:5–102[Medline]
  281. Levy S, Lacombe P, Cointe R, Bru P. High energy transcatheter cardioversion of chronic atrial fibrillation. J Am Coll Cardiol. 1988;12:514–518[Abstract]
  282. Levy S, Lauribe P, Dolla E. A randomized comparison of external and internal cardioversion of chronic atrial fibrillation. Circulation. 1992;86:1415–1420[Abstract/Free Full Text]
  283. Murgatroyd FD, Slade AK, Sopher SM, Rowland E, Ward DE, Camm AJ. Efficacy and tolerability of transvenous low energy cardioversion of paroxysmal atrial fibrillation in humans. J Am Coll Cardiol. 1995;25:1347–1353[Abstract]
  284. Alt E, Schmitt C, Ammer R. Initial experience with intracardiac atrial defibrillation in patients with chronic atrial fibrillation. Pacing Clin Electrophysiol. 1994;17:1067–1078[CrossRef][Medline]
  285. Levy S, Ricard P, Lau CP. Multicenter low energy transvenous atrial defibrillation (XAD) trial results in different subsets of atrial fibrillation. J Am Coll Cardiol. 1997;29:750–755[Abstract]
  286. Levy S, Ricard P, Gueunoun M. Low-energy cardioversion of spontaneous atrial fibrillation: immediate and long-term results. Circulation. 1997;96:253–259[Abstract/Free Full Text]
  287. Schmitt C, Alt E, Plewan A. Low energy intracardiac cardioversion after failed conventional external cardioversion of atrial fibrillation. J Am Coll Cardiol. 1996;28:994–999[Abstract]
  288. Levine PA. Effect of cardioversion and defibrillation on implanted cardiac pacemakers. Barold SS. Modern Cardiac Pacing. Mount Kisco: Futura Publ; 1985. p. 875–876
  289. Pollak A, Falk RH. The use of pacemakers in atrial fibrillation. Falk RH, Podrid PJ. Atrial Fibrillation. New York: Raven Press; 1992. p. 345–347
  290. Prakash A, Saksena S, Mathew P, Krol RB. Internal atrial defibrillation: effect on sinus and atrioventricular nodal function and implanted cardiac pacemakers. Pacing Clin Electrophysiol. 1997;20:2434–2441[CrossRef][Medline]
  291. Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to DC electrical conversion of atrial fibrillation. Am J Cardiol. 1969;23:208–216[CrossRef][Web of Science][Medline]
  292. Arnold AZ, Mick MJ, Mazurek RP, Loop FD, Trohman RG. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol. 1992;19:851–855[Abstract]
  293. Rabbino MD, Likoff W, Dreifus LS. Complications and limitations of direct current countershock. JAMA. 1964;190:417–420[Abstract/Free Full Text]
  294. Lown B, Kleiger R, Williams J. Cardioversion and digitalis drugs: changed threshold to electric shock in digitalized animals. Circ Res. 1965;17:519–531[Abstract/Free Full Text]
  295. Aberg H, Cullhed I. Direct current countershock complications. Acta Med Scand. 1968;183:415–421[Web of Science][Medline]
  296. Ditchey RV, Karliner JS. Safety of electrical cardioversion in patients without digitalis toxicity. Ann Intern Med. 1981;95:676–679[CrossRef][Web of Science][Medline]
  297. Mancini GB, Goldberger AL. Cardioversion of atrial fibrillation: consideration of embolization, anticoagulation, prophylactic pacemaker, and long-term success. Am Heart J. 1982;104:617–621[CrossRef][Web of Science][Medline]
  298. Lipkin DP, Frenneaux M, Stewart R, Joshi J, Lowe T, McKenna WJ. Delayed improvement in exercise capacity after cardioversion of atrial fibrillation to sinus rhythm. Br Heart J. 1988;59:572–577[Abstract/Free Full Text]
  299. Patton JN, Allen JD, Pantridge JF. The effects of shock energy, propranolol, and verapamil on cardiac damage caused by transthoracic countershock. Circulation. 1984;69:357–368[Abstract/Free Full Text]
  300. Van Gelder IC, Crijns HJ, Van der LA, van Gilst WH, Lie KI. Incidence and clinical significance of ST segment elevation after electrical cardioversion of atrial fibrillation and atrial flutter. Am Heart J. 1991;121:51–56[CrossRef][Web of Science][Medline]
  301. Ehsani A, Ewy GA, Sobel BE. Effects of electrical countershock on serum creatine phosphokinase (CPK) isoenzyme activity. Am J Cardiol. 1976;37:12–18[CrossRef][Web of Science][Medline]
  302. Lund M, French JK, Johnson RN, Williams BF, White HD. Serum troponins T and I after elective cardioversion. Eur Heart J. 2000;21:245–253[Abstract/Free Full Text]
  303. Kerr CR, Talajic M, Connolly SJ. Recurrence of atrial fibrillation following its initial diagnosis: follow-up of the Canadian Registry of Atrial Fibrillation (Abstr). Circulation. 1999;100:I-286
  304. Van Gelder IC, Crijns HJ, Tieleman RG. Chronic atrial fibrillation: success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med. 1996;156:2585–2592[Abstract/Free Full Text]
  305. Hohnloser SH, Kuck KH. Atrial fibrillation: maintaining sinus rhythm versus ventricular rate control: the PIAF trial: Pharmacological Intervention in Atrial Fibrillation. J Cardiovasc Electrophysiol. 1998;9:S121–6[Web of Science][Medline]
  306. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). Circulation. 1998;98:2574–2579[Abstract/Free Full Text]
  307. Tuinenburg AE, Van Gelder IC, Van Den Berg MP, Brugemann J, De Kam PJ, Crijns HJ. Lack of prevention of heart failure by serial electrical cardioversion in patients with persistent atrial fibrillation. Heart. 1999;82:486–493[Abstract/Free Full Text]
  308. Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol. 1984;24:129–147[Abstract]
  309. Tieleman RG, Van Gelder IC, Crijns HJ. Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodeling of the atria? J Am Coll Cardiol. 1998;31:167–173[Abstract/Free Full Text]
  310. De Simone A, Stabile G, Vitale DF. Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. J Am Coll Cardiol. 1999;34:810–814[Abstract/Free Full Text]
  311. Anderson JL, Gilbert EM, Alpert BL. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy: a multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Circulation. 1989;80:1557–1570[Abstract/Free Full Text]
  312. Clementy J, Dulhoste MN, Laiter C, Denjoy I, Dos SP. Flecainide acetate in the prevention of paroxysmal atrial fibrillation: a nine-month follow-up of more than 500 patients. Am J Cardiol. 1992;70:44A-9A
  313. Suttorp MJ, Kingma JH, Koomen EM, van 't HA, Tijssen JG, Lie KI. Recurrence of paroxysmal atrial fibrillation or flutter after successful cardioversion in patients with normal left ventricular function. Am J Cardiol. 1993;71:710–713[CrossRef][Web of Science][Medline]
  314. Prystowsky EN. Management of atrial fibrillation: therapeutic options and clinical decisions. Am J Cardiol. 2000;85:3–11
  315. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol. 1997;30:791–798[Abstract]
  316. Roy D, Talajic M, Dorian P. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med. 2000;342:913–920[Abstract/Free Full Text]
  317. Kochiadakis GE, Igoumenidis NE, Marketou ME, Kaleboubas MD, Simantirakis EN, Vardas PE. Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart. 2000;84:251–257[Abstract/Free Full Text]
  318. Chun SH, Sager PT, Stevenson WG, Nademanee K, Middlekauff HR, Singh BN. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol. 1995;76:47–50[CrossRef][Web of Science][Medline]
  319. Horowitz LN, Spielman SR, Greenspan AM. Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol. 1985;6:1402–1407[Abstract]
  320. Tuzcu EM, Gilbo J, Masterson M, Maloney JD. The usefulness of amiodarone in management of refractory supraventricular tachyarrhythmias. Cleve Clin J Med. 1989;56:238–242[Web of Science][Medline]
  321. Vitolo E, Tronci M, Larovere MT, Rumolo R, Morabito A. Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. Acta Cardiol. 1981;36:431–444[Web of Science][Medline]
  322. Gosselink AT, Crijns HJ, Van Gelder IC, Hillige H, Wiesfeld AC, Lie KI. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA. 1992;267:3289–3293[Abstract/Free Full Text]
  323. Gold RL, Haffajee CI, Charos G, Sloan K, Baker S, Alpert JS. Amiodarone for refractory atrial fibrillation. Am J Cardiol. 1986;57:124–127[CrossRef][Web of Science][Medline]
  324. Blevins RD, Kerin NZ, Benaderet D. Amiodarone in the management of refractory atrial fibrillation. Arch Intern Med. 1987;147:1401–1404[Abstract/Free Full Text]
  325. Brodsky MA, Allen BJ, Walker CJ III, Casey TP, Luckett CR, Henry WL. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol. 1987;60:572–575[CrossRef][Web of Science][Medline]
  326. Steeds RP, Birchall AS, Smith M, Channer KS. An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. Heart. 1999;82:170–175[Abstract/Free Full Text]
  327. Kuhlkamp V, Schirdewan A, Stangl K, Homberg M, Ploch M, Beck OA. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2000;36:139–146[Abstract/Free Full Text]
  328. Crijns HJ, Gosselink AT, Lie KI. Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. Cardiovasc Drugs Ther. 1996;10:145–152[CrossRef][Web of Science][Medline]
  329. Nakazawa H, Lythall DA, Noh J. Is there a place for the late cardioversion of atrial fibrillation? A long-term follow-up study of patients with post-thyrotoxic atrial fibrillation. Eur Heart J. 2000;21:327–333[Abstract/Free Full Text]
  330. Hartel G, Louhija A, Konttinen A. Disopyramide in the prevention of recurrence of atrial fibrillation after electroconversion. Clin Pharmacol Ther. 1974;15:551–555[Web of Science][Medline]
  331. Karlson BW, Torstensson I, Abjorn C, Jansson SO, Peterson LE. Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation: a placebo-controlled one-year follow-up study. Eur Heart J. 1988;9:284–290[Abstract/Free Full Text]
  332. Lloyd EA, Gersh BJ, Forman R. The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation: a double-blind study comparing quinidine, disopyramide and placebo. S Afr Med J. 1984;65:367–369[Web of Science][Medline]
  333. Greenbaum RA, Campbell TJ, Channer KS. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide: the EMERALD (European and Australian Multicenter Evaluative Research on Atrial Fibrillation Dofetilide) Study (Abstr). Circulation. 1998;98:I-1633
  334. Pietersen AH, Hellemann H. Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Am J Cardiol. 1991;67:713–717[CrossRef][Web of Science][Medline]
  335. Naccarelli GV, Dorian P, Hohnloser SH, Coumel P. Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. Am J Cardiol. 1996;77:53A–9A[CrossRef][Medline]
  336. Van Wijk LM, den Heijer P, Crijns HJ, van Gilst WH, Lie KI. Flecainide versus quinidine in the prevention of paroxysms of atrial fibrillation. J Cardiovasc Pharmacol. 1989;13:32–36[Web of Science][Medline]
  337. Sonnhag C, Kallryd A, Nylander E, Ryden L. Long-term efficacy of flecainide in paroxysmal atrial fibrillation. Acta Med Scand. 1988;224:563–569[Web of Science][Medline]
  338. Van Gelder IC, Crijns HJ, van Gilst WH, Van Wijk LM, Hamer HP, Lie KI. Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol. 1989;64:1317–1321[CrossRef][Web of Science][Medline]
  339. Geller JC, Geller M, Carlson MD, Waldo AL. Efficacy and safety of moricizine in the maintenance of sinus rhythm in patients with recurrent atrial fibrillation. Am J Cardiol. 2001;87:172–177[CrossRef][Web of Science][Medline]
  340. Circulation. 1995;92:2550–2557[Medline]
  341. Connolly SJ, Hoffert DL. Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. Am J Cardiol. 1989;63:817–819[CrossRef][Web of Science][Medline]
  342. Lee SH, Chen SA, Chiang CE. Comparisons of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: a double-blind, randomized trial. J Intern Med. 1996;239:253–260[CrossRef][Web of Science][Medline]
  343. Reimold SC, Cantillon CO, Friedman PL, Antman EM. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol. 1993;71:558–563[CrossRef][Web of Science][Medline]
  344. Porterfield JG, Porterfield LM. Therapeutic efficacy and safety of oral propafenone for atrial fibrillation. Am J Cardiol. 1989;63:114–116[CrossRef][Web of Science][Medline]
  345. Kerr CR, Klein GJ, Axelson JE, Cooper JC. Propafenone for prevention of recurrent atrial fibrillation. Am J Cardiol. 1988;61:914–916[CrossRef][Web of Science][Medline]
  346. Hammill SC, Wood DL, Gersh BJ, Osborn MJ, Holmes DR Jr. Propafenone for paroxysmal atrial fibrillation. Am J Cardiol. 1988;61:473–474[CrossRef][Web of Science][Medline]
  347. Antman EM, Beamer AD, Cantillon C, McGowan N, Goldman L, Friedman PL. Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter [published erratum appears in J Am Coll Cardiol 1989; 13: 264]. J Am Coll Cardiol. 1988;12:1005–1011[Abstract]
  348. Antman EM, Beamer AD, Cantillon C, McGowan N, Friedman PL. Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs. J Am Coll Cardiol. 1990;15:698–707[Abstract]
  349. Lee SH, Chen SA, Tai CT. Comparisons of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation. Am J Cardiol. 1997;79:905–908[CrossRef][Web of Science][Medline]
  350. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials [published erratum appears in Circulation 1991; 83: 714]. Circulation. 1990;82:1106–1116[Abstract/Free Full Text]
  351. Carlsson J, Tebbe U, Rox J. Cardioversion of atrial fibrillation in the elderly. Am J Cardiol. 1996;78:1380–1384[CrossRef][Web of Science][Medline]
  352. Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation. 1990;82:1932–1939[Abstract/Free Full Text]
  353. Hall JI, Wood DR. Factors affecting cardioversion of atrial arrhythmias with special reference to quinidine. Br Heart J. 1968;30:84–90[Free Full Text]
  354. Radford MD, Evans DW. Long-term results of DC reversion of atrial fibrillation. Br Heart J. 1968;30:91–96[Free Full Text]
  355. Byrne-Quinn E, Wing AJ. Maintenance of sinus rhythm after DC reversion of atrial fibrillation: a double-blind controlled trial of long-acting quinidine bisulphate. Br Heart J. 1970;32:370–376[Abstract/Free Full Text]
  356. Hartel G, Louhija A, Konttinen A, Halonen PI. Value of quinidine in maintenance of sinus rhythm after electric conversion of atrial fibrillation. Br Heart J. 1970;32:57–60[Free Full Text]
  357. Gunning JF, Kristinsson A, Miller G, Saunders K. Long-term follow-up of direct current cardioversion after cardiac surgery with special reference to quinidine. Br Heart J. 1970;32:462–466[Abstract/Free Full Text]
  358. Hillestad L, Bjerkelund C, Dale J, Maltau J, Storstein O. Quinidine in maintenance of sinus rhythm after electroconversion of chronic atrial fibrillation: a controlled clinical study. Br Heart J. 1971;33:518–521[Free Full Text]
  359. Boissel JP, Wolf E, Gillet J. Controlled trial of a long-acting quinidine for maintenance of sinus rhythm after conversion of sustained atrial fibrillation. Eur Heart J. 1981;2:49–55[Abstract/Free Full Text]
  360. Rasmussen K, Wang H, Fausa D. Comparative efficiency of quinidine and verapamil in the maintenance of sinus rhythm after DC conversion of atrial fibrillation: a controlled clinical trial. Acta Med Scand Suppl. 1981;645:23–28[Medline]
  361. Benditt DG, Williams JH, Jin J. Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. Am J Cardiol. 1999;84:270–277[CrossRef][Web of Science][Medline]
  362. Wanless RS, Anderson K, Joy M, Joseph SP. Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. Am Heart J. 1997;133:441–446[CrossRef][Web of Science][Medline]
  363. Kalusche D, Stockinger J, Betz P, Roskamm H. Sotalol and quinidine/verapamil (Cordichin) in chronic atrial fibrillation: conversion and 12-month follow-up: a randomized comparison [in German]. Z Kardiol. 1994;83:109–116[Web of Science][Medline]
  364. Simons GR, Eisenstein EL, Shaw LJ, Mark DB, Pritchett EL. Cost effectiveness of inpatient initiation of antiarrhythmic therapy for supraventricular tachycardias. Am J Cardiol. 1997;80:1551–1557[CrossRef][Web of Science][Medline]
  365. Goethals P, Debruyne P, Saffarian M. Drug-induced Brugada syndrome. Acta Cardiol. 1998;53:157–160[Web of Science][Medline]
  366. Matana A, Goldner V, Stanic K, Mavric Z, Zaputovic L, Matana Z. Unmasking effect of propafenone on the concealed form of the Brugada phenomenon. Pacing Clin Electrophysiol. 2000;23:416–418[CrossRef][Medline]
  367. Feld GK. Atrial fibrillation: is there a safe and highly effective pharmacological treatment? Circulation. 1990;82:2248–2250[Free Full Text]
  368. London F, Howell M. Atrial flutter: 1 to 1 conduction during treatment with quinidine and digitalis. Am Heart J. 1954;48:152–156[Medline]
  369. Leitch JW, Klein GJ, Yee R, Murdock C. Prognostic value of electrophysiology testing in asymptomatic patients with Wolff-Parkinson-White pattern [published erratum appears in Circulation 1991; 83: 1124]. Circulation. 1990;82:1718–1723[Abstract/Free Full Text]
  370. Robertson CE, Miller HC. Extreme tachycardia complicating the use of disopyramide in atrial flutter. Br Heart J. 1980;44:602–603[Abstract/Free Full Text]
  371. Crijns HJ, Van Gelder IC, Lie KI. Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment. Am J Cardiol. 1988;62:1303–1306[CrossRef][Web of Science][Medline]
  372. Timmermans C, Rodriguez LM, Ayers GM, Lambert H, Smeets J, Wellens HJ. Effect of electrode length on atrial defibrillation thresholds. J Cardiovasc Electrophysiol. 1998;9:582–587[Web of Science][Medline]
  373. Rossi M, Lown B. The use of quinidine in cardioversion. Am J Cardiol. 1967;19:234–238[CrossRef][Web of Science][Medline]
  374. Timmermans C, Rodriguez LM, Smeets JL, Wellens HJ. Immediate reinitiation of atrial fibrillation following internal atrial defibrillation. J Cardiovasc Electrophysiol. 1998;9:122–128[Web of Science][Medline]
  375. Van Gelder IC, Crijns HJ, van Gilst WH, De Langen CD, Van Wijk LM, Lie KI. Effects of flecainide on the atrial defibrillation threshold. Am J Cardiol. 1989;63:112–114[CrossRef][Web of Science][Medline]
  376. Oral H, Souza JJ, Michaud GF. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med. 1999;340:1849–1854[Abstract/Free Full Text]
  377. Li H, Natale A, Tomassoni G. Usefulness of ibutilide in facilitating successful external cardioversion of refractory atrial fibrillation. Am J Cardiol. 1999;84:1096–1098[CrossRef][Web of Science][Medline]
  378. Van Noord T, Van Gelder IC, Schoonderwoerd BA, Crijns HJ. Immediate reinitiation of atrial fibrillation after electrical cardioversion predicts subsequent pharmacologic and electrical conversion to sinus rhythm on amiodarone. Am J Cardiol. 2000;86:1384–1385[CrossRef][Web of Science][Medline]
  379. Frick M, Ostergren J, Rosenqvist M. Effect of intravenous magnesium on heart rate and heart rate variability in patients with chronic atrial fibrillation. Am J Cardiol. 1999;84:104–108[CrossRef][Web of Science][Medline]
  380. Singh SN, Fletcher RD, Fisher SG. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia: Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med. 1995;333:77–82[Abstract/Free Full Text]
  381. Julian DG, Prescott RJ, Jackson FS, Szekely P. Controlled trial of sotalol for one year after myocardial infarction. Lancet. 1982;1:1142–1147[CrossRef][Web of Science][Medline]
  382. Julian DG, Camm AJ, Frangin G. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT: European Myocardial Infarct Amiodarone Trial Investigators [published errata appear in Lancet 1997; 349: 1180 and 1997; 349: 1776]. Lancet. 1997;349:667–674[CrossRef][Web of Science][Medline]
  383. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT: Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators [published erratum appears in Lancet 1997; 349: 1776]. Lancet. 1997;349:675–682[CrossRef][Web of Science][Medline]
  384. Hochman JS, Brooks MM, Morris. Prognostic significance of left ventricular aneurysm in the Cardiac Arrhythmia Suppression Trial (CAST) population. Am Heart J. 1994;127:824–832[CrossRef][Web of Science][Medline]
  385. Jackman WM, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis. 1988;31:115–172[CrossRef][Web of Science][Medline]
  386. Ben David J, Zipes DP, Ayers GM, Pride HP. Canine left ventricular hypertrophy predisposes to ventricular tachycardia induction by phase 2 early afterdepolarizations after administration of BAY K 8644. J Am Coll Cardiol. 1992;20:1576–1584[Abstract]
  387. Van Gelder IC, Tuinenburg AE, Schoonderwoerd BS, Tieleman RG, Crijns HJ. Pharmacologic versus direct-current electrical cardioversion of atrial flutter and fibrillation. Am J Cardiol. 1999;84:147R–51R[Web of Science][Medline]
  388. Cox JL, Schuessler RB, D'Agostino HJ Jr. The surgical treatment of atrial fibrillation, III: development of a definitive surgical procedure. J Thorac Cardiovasc Surg. 1991;101:569–583[Abstract]
  389. Hioki M, Ikeshita M, Iedokoro Y. Successful combined operation for mitral stenosis and atrial fibrillation. Ann Thorac Surg. 1993;55:776–778[Abstract]
  390. Nitta T, Lee R, Schuessler RB, Boineau JP, Cox JL. Radial approach: a new concept in surgical treatment for atrial fibrillation, I: concept, anatomic and physiologic bases and development of a procedure. Ann Thorac Surg. 1999;67:27–35[Abstract/Free Full Text]
  391. Melo J, Adragao P, Neves J. Surgery for atrial fibrillation using radiofrequency catheter ablation: assessment of results at one year. Eur J Cardiothorac Surg. 1999;15:851–854[Abstract/Free Full Text]
  392. Jais P, Shah DC, Takahashi A, Hocini M, Haissaguerre M, Clementy J. Long-term follow-up after right atrial radiofrequency catheter treatment of paroxysmal atrial fibrillation. Pacing Clin Electrophysiol. 1998;21:2533–2538[CrossRef][Medline]
  393. Calkins H, Hall J, Ellenbogen K. A new system for catheter ablation of atrial fibrillation. Am J Cardiol. 1999;83:227D–36D[CrossRef][Web of Science][Medline]
  394. Pappone C, Oreto G, Lamberti F. Catheter ablation of paroxysmal atrial fibrillation using a 3D mapping system. Circulation. 1999;100:1203–1208[Abstract/Free Full Text]
  395. Chen SA, Tai CT, Tsai CF, Hsieh MH, Ding YA, Chang MS. Radiofrequency catheter ablation of atrial fibrillation initiated by pulmonary vein ectopic beats. J Cardiovasc Electrophysiol. 2000;11:218–227[Web of Science][Medline]
  396. Haissaguerre M, Jais P, Shah DC. Catheter ablation of chronic atrial fibrillation targeting the reinitiating triggers. J Cardiovasc Electrophysiol. 2000;11:2–10[Web of Science][Medline]
  397. Haissaguerre M, Jais P, Shah DC. Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci. Circulation. 2000;101:1409–1417[Abstract/Free Full Text]
  398. Wellens HJ. Pulmonary vein ablation in atrial fibrillation: hype or hope? Circulation. 2000;102:2562–2564[Free Full Text]
  399. Natale A, Newby KH, Pisano E. Prospective randomized comparison of antiarrhythmic therapy versus first-line radiofrequency ablation in patients with atrial flutter. J Am Coll Cardiol. 2000;35:1898–1904[Abstract/Free Full Text]
  400. Andersen HR, Nielsen JC, Thomsen PE. Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome. Lancet. 1997;350:1210–1216[CrossRef][Web of Science][Medline]
  401. Gillis AM, Wyse DG, Connolly SJ. Atrial pacing periablation for prevention of paroxysmal atrial fibrillation. Circulation. 1999;99:2553–2558[Abstract/Free Full Text]
  402. Delfaut P, Saksena S, Prakash A, Krol RB. Long-term outcome of patients with drug-refractory atrial flutter and fibrillation after single- and dual-site right atrial pacing for arrhythmia prevention. J Am Coll Cardiol. 1998;32:1900–1908[Abstract/Free Full Text]
  403. Fitts SM, Hill MR, Mehra R. Design and implementation of the Dual Site Atrial Pacing to Prevent Atrial Fibrillation (DAPPAF) clinical trial. J Interv Card Electrophysiol. 1998;2:139–144[CrossRef][Web of Science][Medline]
  404. Ayers GM, Alferness CA, Ilina M. Ventricular proarrhythmic effects of ventricular cycle length and shock strength in a sheep model of transvenous atrial defibrillation. Circulation. 1994;89:413–422[Abstract/Free Full Text]
  405. Levy S, Rodriguez LM, Camm J. Number, duration and frequency of nontreated atrial fibrillation episodes observed during the metrix automatic implantable defibrillator trial (Abstr). PACE. 1998;21:811
  406. Chorro FJ, Kirchhof CJ, Brugada J, Allessie MA. Ventricular response during irregular atrial pacing and atrial fibrillation. Am J Physiol. 1990;259:H1015–21[Web of Science][Medline]
  407. Rawles JM. What is meant by a ‘controlled’ ventricular rate in atrial fibrillation? Br Heart J. 1990;63:157–161[Abstract/Free Full Text]
  408. Resnekov L, McDonald L. Electroversion of lone atrial fibrillation and flutter including haemodynamic studies at rest and on exercise. Br Heart J. 1971;33:339–350[Free Full Text]
  409. Atwood JE, Myers J, Sandhu S. Optimal sampling interval to estimate heart rate at rest and during exercise in atrial fibrillation. Am J Cardiol. 1989;63:45–48[CrossRef][Web of Science][Medline]
  410. Stein KM, Borer JS, Hochreiter C, Devereux RB, Kligfield P. Variability of the ventricular response in atrial fibrillation and prognosis in chronic nonischemic mitral regurgitation. Am J Cardiol. 1994;74:906–911[CrossRef][Web of Science][Medline]
  411. Frey B, Heinz G, Binder T. Diurnal variation of ventricular response to atrial fibrillation in patients with advanced heart failure. Am Heart J. 1995;129:58–65[CrossRef][Web of Science][Medline]
  412. Coumel P, Thomas O, Leenhardt A. Drug therapy for prevention of atrial fibrillation. Am J Cardiol. 1996;77:3A–9A[CrossRef][Medline]
  413. Roberts SA, Diaz C, Nolan PE. Effectiveness and costs of digoxin treatment for atrial fibrillation and flutter. Am J Cardiol. 1993;72:567–573[CrossRef][Web of Science][Medline]
  414. Lemery R, Brugada P, Cheriex E, Wellens HJ. Reversibility of tachycardia-induced left ventricular dysfunction after closed-chest catheter ablation of the atrioventricular junction for intractable atrial fibrillation. Am J Cardiol. 1987;60:1406–1408[CrossRef][Web of Science][Medline]
  415. Rawles JM, Metcalfe MJ, Jennings K. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br Heart J. 1990;63:225–227[Abstract/Free Full Text]
  416. Farshi R, Kistner D, Sarma JS, Longmate JA, Singh BN. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol. 1999;33:304–310[Abstract/Free Full Text]
  417. Hays JV, Gilman JK, Rubal BJ. Effect of magnesium sulfate on ventricular rate control in atrial fibrillation. Ann Emerg Med. 1994;24:61–64[Web of Science][Medline]
  418. Ellenbogen KA, Dias VC, Plumb VJ, Heywood JT, Mirvis DM. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multicenter study. J Am Coll Cardiol. 1991;18:891–897[Abstract]
  419. Rinkenberger RL, Prystowsky EN, Heger JJ, Troup PJ, Jackman WM, Zipes DP. Effects of intravenous and chronic oral verapamil administration in patients with supraventricular tachyarrhythmias. Circulation. 1980;62:996–1010[Free Full Text]
  420. McGovern B, Garan H, Ruskin JN. Precipitation of cardiac arrest by verapamil in patients with Wolff-Parkinson-White syndrome. Ann Intern Med. 1986;104:791–794[CrossRef][Web of Science][Medline]
  421. Gulamhusein S, Ko P, Klein GJ. Ventricular fibrillation following verapamil in the Wolff-Parkinson-White syndrome. Am Heart J. 1983;106:145–147[CrossRef][Web of Science][Medline]
  422. Balser JR, Martinez EA, Winters BD. Beta-adrenergic blockade accelerates conversion of postoperative supraventricular tachyarrhythmias. Anesthesiology. 1998;89:1052–1059[CrossRef][Web of Science][Medline]
  423. Clemo HF, Wood MA, Gilligan DM, Ellenbogen KA. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol. 1998;81:594–598[CrossRef][Web of Science][Medline]
  424. Segal JB, McNamara RL, Miller MR. The evidence regarding the drugs used for ventricular rate control. J Fam Pract. 2000;49:47–59[Web of Science][Medline]
  425. Anderson JL, Prystowsky EN. Sotalol: an important new antiarrhythmic. Am Heart J. 1999;137:388–409[CrossRef][Web of Science][Medline]
  426. Lewis RV, McMurray J, McDevitt DG. Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. J Cardiovasc Pharmacol. 1989;13:1–6[Web of Science][Medline]
  427. Circulation. 1995;92:2764–2784[Free Full Text]
  428. Blumgart H. The reaction to exercise of the heart affected by auricular fibrillation. Heart. 1924;11:49–56[Web of Science]
  429. Scardi S, Humar F, Pandullo C, Poletti A. Oral clonidine for heart rate control in chronic atrial fibrillation (Letter). Lancet. 1993;341:1211–1212[Web of Science][Medline]
  430. Wittkampf FH, de Jongste MJ, Lie HI, Meijler FL. Effect of right ventricular pacing on ventricular rhythm during atrial fibrillation. J Am Coll Cardiol. 1988;11:539–545[Abstract]
  431. Williamson BD, Man KC, Daoud E, Niebauer M, Strickberger SA, Morady F. Radiofrequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation [published erratum appears in N Engl J Med 1995; 332: 479]. N Engl J Med. 1994;331:910–917[Abstract/Free Full Text]
  432. Feld GK, Fleck RP, Fujimura O, Prothro DL, Bahnson TD, Ibarra M. Control of rapid ventricular response by radiofrequency catheter modification of the atrioventricular node in patients with medically refractory atrial fibrillation. Circulation. 1994;90:2299–2307[Abstract/Free Full Text]
  433. Evans GT Jr, Scheinman MM, Bardy G. Predictors of in-hospital mortality after DC catheter ablation of atrioventricular junction: results of a prospective, international, multicenter study. Circulation. 1991;84:1924–1937[Abstract/Free Full Text]
  434. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. J Am Coll Cardiol. 2000;35:183–187[Abstract/Free Full Text]
  435. Lancet. 1996;348:633–638[CrossRef][Web of Science][Medline]
  436. Lancet. 1993;342:1255–1262[Web of Science][Medline]
  437. Moulton AW, Singer DE, Haas JS. Risk factors for stroke in patients with nonrheumatic atrial fibrillation: a case-control study. Am J Med. 1991;91:156–161[CrossRef][Web of Science][Medline]
  438. J Stroke Cerebrovasc Dis. 1995;5:147–157
  439. Boysen G, Nyboe J, Appleyard M. Stroke incidence and risk factors for stroke in Copenhagen, Denmark. Stroke. 1988;19:1345–1353[Abstract/Free Full Text]
  440. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 1989;87:144–152[Web of Science][Medline]
  441. Beyth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin: a randomized, controlled trial. Ann Intern Med. 2000;133:687–695[Abstract/Free Full Text]
  442. Hurley DM, Hunter AN, Hewett MJ, Stockigt JR. Atrial fibrillation and arterial embolism in hyperthyroidism. Aust NZJ Med. 1981;11:391–393[Web of Science][Medline]
  443. Yuen RW, Gutteridge DH, Thompson PL, Robinson JS. Embolism in thyrotoxic atrial fibrillation. Med J Aust. 1979;1:630–631[Web of Science][Medline]
  444. Staffurth JS, Gibberd MC, Fui SN. Arterial embolism in thyrotoxicosis with atrial fibrillation. BMJ. 1977;2:688–690[Abstract/Free Full Text]
  445. Bar-Sela S, Ehrenfeld M, Eliakim M. Arterial embolism in thyrotoxicosis with atrial fibrillation. Arch Intern Med. 1981;141:1191–1192[Abstract/Free Full Text]
  446. Petersen P, Hansen JM. Stroke in thyrotoxicosis with atrial fibrillation. Stroke. 1988;19:15–18[Abstract/Free Full Text]
  447. Petersen P. Thromboembolic complications in atrial fibrillation. Stroke. 1990;21:4–13[Abstract/Free Full Text]
  448. Savage DD, Seides SF, Maron BJ, Myers DJ, Epstein SE. Prevalence of arrhythmias during 24-hour electrocardiographic monitoring and exercise testing in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. Circulation. 1979;59:866–875[Abstract/Free Full Text]
  449. Robinson K, Frenneaux MP, Stockins B, Karatasakis G, Poloniecki JD, McKenna WJ. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol. 1990;15:1279–1285[Abstract]
  450. Russell JW, Biller J, Hajduczok ZD, Jones MP, Kerber RE, Adams HP Jr. Ischemic cerebrovascular complications and risk factors in idiopathic hypertrophic subaortic stenosis. Stroke. 1991;22:1143–1147[Abstract/Free Full Text]
  451. Shigematsu Y, Hamada M, Mukai M, Matsuoka H, Sumimoto T, Hiwada K. Mechanism of atrial fibrillation and increased incidence of thromboembolism in patients with hypertrophic cardiomyopathy. Jpn Circ J. 1995;59:329–336[Medline]
  452. Higashikawa M, Nakamura Y, Yoshida M, Kinoshita M. Incidence of ischemic strokes in hypertrophic cardiomyopathy is markedly increased if complicated by atrial fibrillation. Jpn Circ J. 1997;61:673–681[CrossRef][Medline]
  453. N Engl J Med. 1990;323:1505–1511[Abstract]
  454. JAMA. 1998;279:1273–1277[Abstract/Free Full Text]
  455. Ann Intern Med. 1998;128:639–647[Abstract/Free Full Text]
  456. Fatkin D, Kuchar DL, Thorburn CW, Feneley MP. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for ‘atrial stunning’ as a mechanism of thromboembolic complications. J Am Coll Cardiol. 1994;23:307–316[Abstract]
  457. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492–501[Abstract/Free Full Text]
  458. Hellemons BS, Langenberg M, Lodder J. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ. 1999;319:958–964[Abstract/Free Full Text]
  459. Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson AK, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest. 1998;114:579S–89S[Medline]
  460. Pearce LA, Hart RG, Halperin JL. Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. Am J Med. 2000;109:45–51[CrossRef][Web of Science][Medline]
  461. Singer DE. Patients with atrial fibrillation at low risk of stroke (Letter). JAMA. 1998;280:882–883[CrossRef][Medline]
  462. Howitt A, Armstrong D. Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation. BMJ. 1999;318:1324–1327[Abstract/Free Full Text]
  463. Wood KA, Eisenberg SJ, Kalman JM. Risk of thromboembolism in chronic atrial flutter. Am J Cardiol. 1997;79:1043–1047[CrossRef][Web of Science][Medline]
  464. Biblo LA, Yuan Z, Quan KJ, Mackall JA, Rimm AA. Risk of stroke in patients with atrial flutter. Am J Cardiol. 2001;87:346–349[CrossRef][Web of Science][Medline]
  465. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet. 1989;1:175–179[Web of Science][Medline]
  466. Ezekowitz MD, Bridgers SL, James KE. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation [published erratum appears in N Engl J Med 1993; 328: 148]. N Engl J Med. 1992;327:1406–1412[Abstract]
  467. Arch Intern Med. 1996;156:409–416[Abstract/Free Full Text]
  468. Gorter JW. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Neurology. 1999;53:1319–1327[Abstract/Free Full Text]
  469. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120:897–902[Abstract/Free Full Text]
  470. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med. 1996;124:970–979[Abstract/Free Full Text]
  471. Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet. 1998;352:1167–1171[CrossRef][Web of Science][Medline]
  472. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335:540–546[Abstract/Free Full Text]
  473. N Engl J Med. 1995;333:5–10[Abstract/Free Full Text]
  474. Hart RG. Intensity of anticoagulation to prevent stroke in patients with atrial fibrillation (Letter). Ann Intern Med. 1998;128:408[Free Full Text]
  475. Minematsu K, Yasaka M, Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a prospective, randomized, multicenter trial (Abstr). Stroke. 1999;30:241
  476. Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest. 2001;119:220S–7S[CrossRef][Web of Science][Medline]
  477. Bonow RO, Carabello B, de LA Jr. Guidelines for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation. 1998;98:1949–1984[Free Full Text]
  478. Hirsh J, Warkentin TE, Shaughnessy SG. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119:64S–94S[CrossRef][Web of Science][Medline]
  479. Warkentin TE, Levine MN, Hirsh J. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330–1335[Abstract/Free Full Text]
  480. Murray RD, Deitcher SR, Shah A. Potential clinical efficacy and cost benefit of a transesophageal echocardiography-guided low-molecular-weight heparin (enoxaparin) approach to antithrombotic therapy in patients undergoing immediate cardioversion from atrial fibrillation. J Am Soc Echocardiogr. 2001;14:200–208[CrossRef][Web of Science][Medline]
  481. Arch Intern Med. 1997;157:1237–1240[Abstract/Free Full Text]
  482. Munger TM, Packer DL, Hammill SC. A population study of the natural history of Wolff-Parkinson-White syndrome in Olmsted County, Minnesota, 1953–1989. Circulation. 1993;87:866–873[Abstract/Free Full Text]
  483. Hart RG, Benavente O, Pearce LA. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis. Cerebrovasc Dis. 1999;9:215–217[CrossRef][Web of Science][Medline]
  484. Gullov AL, Koefoed BG, Petersen P. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study: Atrial Fibrillation Aspirin and Anticoagulation. Arch Intern Med. 1999;159:1322–1328[Abstract/Free Full Text]
  485. Lancet. 1994;343:687–691[CrossRef][Web of Science][Medline]
  486. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18:349–355[Abstract]
  487. Morocutti C, Amabile G, Fattapposta F. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. Stroke. 1997;28:1015–1021[Abstract/Free Full Text]
  488. Pengo V, Zasso A, Barbero F. Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation. Am J Cardiol. 1998;82:433–437[CrossRef][Web of Science][Medline]
  489. Harenberg J, Weuster B, Pfitzer M. Prophylaxis of embolic events in patients with atrial fibrillation using low molecular weight heparin. Semin Thromb Hemost. 1993;19:116–121[Web of Science][Medline]
  490. Posada IS, Barriales V. Alternate-day dosing of aspirin in atrial fibrillation. Am Heart J. 1999;138:137–143[CrossRef][Web of Science][Medline]
  491. Stroke. 1990;21:1122–1130[Abstract/Free Full Text]
  492. Naccarelli GV, Dell'Orfano JT, Wolbrette DL, Patel HM, Luck JC. Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy. Am J Cardiol. 2000;85:36D–45D[Web of Science][Medline]
  493. Moreyra E, Finkelhor RS, Cebul RD. Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardioversion from atrial fibrillation and flutter: an analysis of pooled trials. Am Heart J. 1995;129:71–75[CrossRef][Web of Science][Medline]
  494. Van Gelder IC, Crijns HJ, Blanksma PK. Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease. Am J Cardiol. 1993;72:560–566[CrossRef][Web of Science][Medline]
  495. Petersen P, Kastrup J, Videbaek R, Boysen G. Cerebral blood flow before and after cardioversion of atrial fibrillation. J Cereb Blood Flow Metab. 1989;9:422–425[Web of Science][Medline]
  496. Antonielli E, Pizzuti A, Bassignana A. Transesophageal echocardiographic evidence of more pronounced left atrial stunning after chemical (propafenone) rather than electrical attempts at cardioversion from atrial fibrillation. Am J Cardiol. 1999;84:1092–1010[CrossRef][Web of Science][Medline]
  497. Falcone RA, Morady F, Armstrong WF. Transesophageal echocardiographic evaluation of left atrial appendage function and spontaneous contrast formation after chemical or electrical cardioversion of atrial fibrillation. Am J Cardiol. 1996;78:435–439[CrossRef][Web of Science][Medline]
  498. Bellotti P, Spirito P, Lupi G, Vecchio C. Left atrial appendage function assessed by transesophageal echocardiography before and on the day after elective cardioversion for nonvalvular atrial fibrillation. Am J Cardiol. 1998;81:1199–1202[CrossRef][Web of Science][Medline]
  499. Harjai K, Mobarek S, Abi-Samra F. Mechanical dysfunction of the left atrium and the left atrial appendage following cardioversion of atrial fibrillation and its relation to total electrical energy used for cardioversion. Am J Cardiol. 1998;81:1125–1129[CrossRef][Web of Science][Medline]
  500. Sparks PB, Jayaprakash S, Vohra JK. Left atrial ‘stunning’ following radiofrequency catheter ablation of chronic atrial flutter. J Am Coll Cardiol. 1998;32:468–475[Abstract/Free Full Text]
  501. Manning WJ, Silverman DI, Katz SE. Temporal dependence of the return of atrial mechanical function on the mode of cardioversion of atrial fibrillation to sinus rhythm. Am J Cardiol. 1995;75:624–626[CrossRef][Web of Science][Medline]
  502. Grimm RA, Leung DY, Black IW, Stewart WJ, Thomas JD, Klein AL. Left atrial appendage ‘stunning’ after spontaneous conversion of atrial fibrillation demonstrated by transesophageal Doppler echocardiography. Am Heart J. 1995;130:174–176[CrossRef][Web of Science][Medline]
  503. Berger M, Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol. 1998;82:1545–1547[CrossRef][Web of Science][Medline]
  504. Mehta D, Baruch L. Thromboembolism following cardioversion of ‘common’ atrial flutter: risk factors and limitations of transesophageal echocardiography. Chest. 1996;110:1001–1003[CrossRef][Web of Science][Medline]
  505. Irani WN, Grayburn PA, Afridi I. Prevalence of thrombus, spontaneous echo contrast, and atrial stunning in patients undergoing cardioversion of atrial flutter: a prospective study using transesophageal echocardiography. Circulation. 1997;95:962–966[Abstract/Free Full Text]
  506. Lazzeroni E, Picano E, Morozzi L. Dipyridamole-induced ischemia as a prognostic marker of future adverse cardiac events in adult patients with hypertrophic cardiomyopathy. Circulation. 1997;96:4268–4272[Abstract/Free Full Text]
  507. Soria R, Guize L, Chretien JM. The natural history of 270 cases of Wolff-Parkinson-White syndrome in a survey of the general population [in French]. Arch Mal Coeur Vaiss. 1989;82:331–336[Web of Science][Medline]
  508. Creswell LL, Schuessler RB, Rosenbloom M, Cox JL. Hazards of postoperative atrial arrhythmias. Ann Thorac Surg. 1993;56:539–549[Abstract]
  509. Andrews TC, Reimold SC, Berlin JA, Antman EM. Prevention of supraventricular arrhythmias after coronary artery bypass surgery: a meta-analysis of randomized control trials. Circulation. 1991;84:III-236–III-244[Medline]
  510. Stebbins D, Igidbashian L, Goldman SM. Clinical outcome of patients who develop atrial fibrillation after coronary artery bypass graft surgery (Abstr). PACE. 1995;18:798
  511. Dixon FE, Genton E, Vacek JL, Moore CB, Landry J. Factors predisposing to supraventricular tachyarrhythmias after coronary artery bypass grafting. Am J Cardiol. 1986;58:476–478[CrossRef][Web of Science][Medline]
  512. Leitch JW, Thomson D, Baird DK, Harris PJ. The importance of age as a predictor of atrial fibrillation and flutter after coronary artery bypass grafting. J Thorac Cardiovasc Surg. 1990;100:338–342[Abstract]
  513. Fuller JA, Adams GG, Buxton B. Atrial fibrillation after coronary artery bypass grafting: is it a disorder of the elderly? J Thorac Cardiovasc Surg. 1989;97:821–825[Abstract]
  514. Aranki SF, Shaw DP, Adams DH. Predictors of atrial fibrillation after coronary artery surgery: current trends and impact on hospital resources. Circulation. 1996;94:390–397[Abstract/Free Full Text]
  515. Caretta Q, Mercanti CA, De Nardo D. Ventricular conduction defects and atrial fibrillation after coronary artery bypass grafting: multivariate analysis of preoperative, intraoperative and postoperative variables. Eur Heart J. 1991;12:1107–1111[Abstract/Free Full Text]
  516. Falk RH. Etiology and complications of atrial fibrillation: insights from pathology studies. Am J Cardiol. 1998;82:10N–7N[CrossRef][Web of Science][Medline]
  517. Cox JL. A perspective of postoperative atrial fibrillation in cardiac operations (Editorial). Ann Thorac Surg. 1993;56:405–409[Web of Science][Medline]
  518. Page P, Hassanalizadeh H, Cardinal R. Transition between atrial fibrillation, unstable or sustained flutter, and sinus rhythm during procainamide injection or vagal stimulation in dogs with sterile pericarditis. Circulation. 1988;78:II-613
  519. Matangi MF, Neutze JM, Graham KJ, Hill DG, Kerr AR, Barratt-Boyes BG. Arrhythmia prophylaxis after aorta-coronary bypass: the effect of minidose propranolol. J Thorac Cardiovasc Surg. 1985;89:439–443[Abstract]
  520. Parikka H, Toivonen L, Heikkila L, Virtanen K, Jarvinen A. Comparison of sotalol and metoprolol in the prevention of atrial fibrillation after coronary artery bypass surgery. J Cardiovasc Pharmacol. 1998;31:67–73[CrossRef][Web of Science][Medline]
  521. Gomes JA, Ip J, Santoni-Rugiu F. Oral d,l sotalol reduces the incidence of postoperative atrial fibrillation in coronary artery bypass surgery patients: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 1999;34:334–339[Abstract/Free Full Text]
  522. Daoud EG, Strickberger SA, Man KC. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. N Engl J Med. 1997;337:1785–1791[Abstract/Free Full Text]
  523. Guarnieri T, Nolan S, Gottlieb SO, Dudek A, Lowry DR. Intravenous amiodarone for the prevention of atrial fibrillation after open heart surgery: the Amiodarone Reduction in Coronary Heart (ARCH) trial. J Am Coll Cardiol. 1999;34:343–347[Abstract/Free Full Text]
  524. Kowey PR, Taylor JE, Rials SJ, Marinchak RA. Meta-analysis of the effectiveness of prophylactic drug therapy in preventing supraventricular arrhythmia early after coronary artery bypass grafting. Am J Cardiol. 1992;69:963–965[CrossRef][Web of Science][Medline]
  525. Podrid PJ. Prevention of postoperative atrial fibrillation: what is the best approach? J Am Coll Cardiol. 1999;34:340–342[Free Full Text]
  526. Gold MR, O'Gara PT, Buckley MJ, DeSanctis RW. Efficacy and safety of procainamide in preventing arrhythmias after coronary artery bypass surgery. Am J Cardiol. 1996;78:975–979[CrossRef][Web of Science][Medline]
  527. Fan K, Lee KL, Chiu CS. Effects of biatrial pacing in prevention of postoperative atrial fibrillation after coronary artery bypass surgery. Circulation. 2000;102:755–760[Abstract/Free Full Text]
  528. Chapman MJ, Moran JL, O'Fathartaigh MS, Peisach AR, Cunningham DN. Management of atrial tachyarrhythmias in the critically ill: a comparison of intravenous procainamide and amiodarone. Intensive Care Med. 1993;19:48–52[CrossRef][Web of Science][Medline]
  529. McAlister HF, Luke RA, Whitlock RM, Smith WM. Intravenous amiodarone bolus versus oral quinidine for atrial flutter and fibrillation after cardiac operations. J Thorac Cardiovasc Surg. 1990;99:911–918[Abstract]
  530. Hjelms E. Procainamide conversion of acute atrial fibrillation after open-heart surgery compared with digoxin treatment. Scand J Thorac Cardiovasc Surg. 1992;26:193–196[Web of Science][Medline]
  531. Gray RJ, Bateman TM, Czer LS, Conklin CM, Matloff JM. Esmolol: a new ultrashort-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias. J Am Coll Cardiol. 1985;5:1451–1456[Abstract]
  532. VanderLugt JT, Mattioni T, Denker S. Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery. Circulation. 1999;100:369–375[Abstract/Free Full Text]
  533. Reed GL III, Singer DE, Picard EH, DeSanctis RW. Stroke following coronary-artery bypass surgery: a case-control estimate of the risk from carotid bruits. N Engl J Med. 1988;319:1246–1250[Abstract]
  534. Taylor GJ, Malik SA, Colliver JA. Usefulness of atrial fibrillation as a predictor of stroke after isolated coronary artery bypass grafting. Am J Cardiol. 1987;60:905–907[CrossRef][Web of Science][Medline]
  535. Wells JL Jr, MacLean WA, James TN, Waldo AL. Characterization of atrial flutter: studies in man after open heart surgery using fixed atrial electrodes. Circulation. 1979;60:665–673[Free Full Text]
  536. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. The occurrence and prognostic significance of atrial fibrillation/flutter following acute myocardial infarction. Eur Heart J. 1999;20:748–754[Abstract/Free Full Text]
  537. Crenshaw BS, Ward SR, Granger CB, Stebbins AL, Topol EJ, Califf RM. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience: Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol. 1997;30:406–413[Abstract]
  538. Eldar M, Canetti M, Rotstein Z. Significance of paroxysmal atrial fibrillation complicating acute myocardial infarction in the thrombolytic era. Circulation. 1998;97:965–970[Abstract/Free Full Text]
  539. Ryan TJ, Antman EM, Brooks NH. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1999;34:890–911[Free Full Text]
  540. Goldberg RJ, Seeley D, Becker RC. Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: a community-wide perspective. Am Heart J. 1990;119:996–1001[CrossRef][Web of Science][Medline]
  541. Behar S, Zahavi Z, Goldbourt U, Reicher-Reiss H. Long-term prognosis of patients with paroxysmal atrial fibrillation complicating acute myocardial infarction. Eur Heart J. 1992;13:45–50[Abstract/Free Full Text]
  542. Flensted-Jensen E. Wolff-Parkinson-White syndrome: a long-term follow-up of 47 cases. Acta Med Scand. 1969;186:65–74[Web of Science][Medline]
  543. Zardini M, Yee R, Thakur RK, Klein GJ. Risk of sudden arrhythmic death in the Wolff-Parkinson-White syndrome: current perspectives. Pacing Clin Electrophysiol. 1994;17:966–975[CrossRef][Medline]
  544. Jackman WM, Wang XZ, Friday KJ. Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by radiofrequency current. N Engl J Med. 1991;324:1605–1611[Abstract]
  545. Davidson E, Weinberger I, Rotenberg Z, Fuchs J, Agmon J. Atrial fibrillation: cause and time of onset. Arch Intern Med. 1989;149:457–459[Abstract/Free Full Text]
  546. Agner T, Almdal T, Thorsteinsson B, Agner E. A reevaluation of atrial fibrillation in thyrotoxicosis. Dan Med Bull. 1984;31:157–159[Web of Science][Medline]
  547. Nakazawa HK, Sakurai K, Hamada N, Momotani N, Ito K. Management of atrial fibrillation in the post-thyrotoxic state. Am J Med. 1982;72:903–906[CrossRef][Web of Science][Medline]
  548. Clozel JP, Danchin N, Genton P, Thomas JL, Cherrier F. Effects of propranolol and of verapamil on heart rate and blood pressure in hyperthyroidism. Clin Pharmacol Ther. 1984;36:64–69[Web of Science][Medline]
  549. Hirsh J. Oral anticoagulant drugs. N Engl J Med. 1991;324:1865–1875[Web of Science][Medline]
  550. Bhanderi AK, Isher N. Cardiac arrhythmias and pregnancies. Gleicher N. Principles and Practice of Medical Therapy in Pregnancy. Stamford: Appleton & Lange; 1998. p. 975–987
  551. Bryg RJ, Gordon PR, Kudesia VS, Bhatia RK. Effect of pregnancy on pressure gradient in mitral stenosis. Am J Cardiol. 1989;63:384–386[CrossRef][Web of Science][Medline]
  552. Whittemore R, Hobbins JC, Engle MA. Pregnancy and its outcome in women with and without surgical treatment of congenital heart disease. Am J Cardiol. 1982;50:641–651[CrossRef][Web of Science][Medline]
  553. Forfar JC, Miller HC, Toft AD. Occult thyrotoxicosis: a correctable cause of ‘idiopathic’ atrial fibrillation. Am J Cardiol. 1979;44:9–12[CrossRef][Web of Science][Medline]
  554. Page RL. Treatment of arrhythmias during pregnancy. Am Heart J. 1995;130:871–876[CrossRef][Web of Science][Medline]
  555. Cox JL, Gardner MJ. Cardiovascular drugs in pregnancy and lactation. Gleicher N, Gall SA, Sibai BM. Principles and Practice of Medical Therapy in Pregnancy. Stamford: Appleton & Lange; 1998. p. 911–926
  556. Chow T, Galvin J, McGovern B. Antiarrhythmic drug therapy in pregnancy and lactation. Am J Cardiol. 1998;82:58I–62I[CrossRef][Web of Science][Medline]
  557. Lownes HE, Ives TJ. Mexiletine use in pregnancy and lactation. Am J Obstet Gynecol. 1987;157:446–447[Web of Science][Medline]
  558. Wagner X, Jouglard J, Moulin M, Miller AM, Petitjean J, Pisapia A. Coadministration of flecainide acetate and sotalol during pregnancy: lack of teratogenic effects, passage across the placenta, and excretion in human breast milk. Am Heart J. 1990;119:700–702[Web of Science][Medline]
  559. Ovadia M, Brito M, Hoyer GL, Marcus FI. Human experience with amiodarone in the embryonic period. Am J Cardiol. 1994;73:316–317[CrossRef][Web of Science][Medline]
  560. Magee LA, Downar E, Sermer M, Boulton BC, Allen LC, Koren G. Pregnancy outcome after gestational exposure to amiodarone in Canada. Am J Obstet Gynecol. 1995;172:1307–1311[CrossRef][Web of Science][Medline]
  561. Foster CJ, Love HG. Amiodarone in pregnancy: case report and review of the literature. Int J Cardiol. 1988;20:307–316[CrossRef][Web of Science][Medline]
  562. Leung CY, Brodsky MA. Cardiac arrhythmias and pregnancy: diagnosis and management of maternal and fetal disease. Elkayam U, Gleicher N. Cardiac Problems in Pregnancy. New York: Wiley-Liss; 1998. p. 155–175
  563. Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest. 2001;119:122S–31S[CrossRef][Web of Science][Medline]
  564. Stevenson RE, Burton OM, Ferlauto GJ, Taylor HA. Hazards of oral anticoagulants during pregnancy. JAMA. 1980;243:1549–1551[Abstract/Free Full Text]
  565. Iturbe-Alessio I, Fonseca MC, Mutchinik O, Santos MA, Zajarias A, Salazar E. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med. 1986;315:1390–1393[Abstract]
  566. Ginsberg JS, Kowalchuk G, Hirsh J, Brill-Edwards P, Burrows R. Heparin therapy during pregnancy: risks to the fetus and mother. Arch Intern Med. 1989;149:2233–2236[Abstract/Free Full Text]
  567. Elkayam UR. Anticoagulation in pregnant women with prosthetic heart valves: a double jeopardy. J Am Coll Cardiol. 1996;27:1704–1706[CrossRef][Web of Science][Medline]
  568. Anderson DR, Ginsberg JS, Brill-Edwards P, Demers C, Burrows RF, Hirsh J. The use of an indwelling Teflon catheter for subcutaneous heparin administration during pregnancy: a randomized crossover study. Arch Intern Med. 1993;153:841–844[Abstract/Free Full Text]
  569. Vitale N, De Feo M, De Santo LS, Pollice A, Tedesco N, Cotrufo M. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol. 1999;33:1637–1641[Abstract/Free Full Text]
  570. Maron BJ, Olivotto I, Spirito P. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation. 2000;102:858–864[Abstract/Free Full Text]
  571. McKenna WJ, England D, Doi YL, Deanfield JE, Oakley C, Goodwin JF. Arrhythmia in hypertrophic cardiomyopathy, I: influence on prognosis. Br Heart J. 1981;46:168–172[Abstract/Free Full Text]
  572. Shih HT, Webb CR, Conway WA, Peterson E, Tilley B, Goldstein S. Frequency and significance of cardiac arrhythmias in chronic obstructive lung disease. Chest. 1988;94:44–48[CrossRef][Web of Science][Medline]
  573. Hudson LD, Kurt TL, Petty TL, Genton E. Arrhythmias associated with acute respiratory failure in patients with chronic airway obstruction. Chest. 1973;63:661–665[CrossRef][Web of Science][Medline]
  574. Fuso L, Incalzi RA, Pistelli R. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med. 1995;98:272–277[CrossRef][Web of Science][Medline]
  575. Payne RM. Management of arrhythmias in patients with severe lung disease. Clin Pulm Med. 1994;1:232–237[CrossRef]
  576. Andersen HR, Thuesen L, Bagger JP, Vesterlund T, Thomsen PE. Prospective randomised trial of atrial versus ventricular pacing in sick-sinus syndrome. Lancet. 1994;344:1523–1528[CrossRef][Web of Science][Medline]
  577. Connolly SJ, Kerr CR, Gent M. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. N Engl J Med. 2000;342:1385–1391[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 EuropaceHome page
M. Nabauer, A. Gerth, T. Limbourg, S. Schneider, M. Oeff, P. Kirchhof, A. Goette, T. Lewalter, U. Ravens, T. Meinertz, et al.
The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management
Europace, April 1, 2009; 11(4): 423 - 434.
[Abstract] [Full Text] [PDF]

Home page
 EuropaceHome page
R. Pisters, R. Nieuwlaat, C. B. de Vos, and H. J. Crijns
Comprehensive upstream treatment for atrial fibrillation, when and how?
Europace, April 1, 2009; 11(4): 397 - 399.
[Full Text] [PDF]

Home page
 EuropaceHome page
K. Kato, T. Fujimaki, T. Yoshida, M. Oguri, K. Yajima, T. Hibino, and T. Murohara
Impact of matrix metalloproteinase-2 levels on long-term outcome following pharmacological or electrical cardioversion in patients with atrial fibrillation
Europace, March 1, 2009; 11(3): 332 - 337.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
N Perez-Castellano, J Villacastin, J Salinas, J Moreno, M Doblado, E Ruiz, R Isa, and C Macaya
Cooled ablation reduces pulmonary vein isolation time: results of a prospective randomised trial
Heart, February 1, 2009; 95(3): 203 - 209.
[Abstract] [Full Text] [PDF]

Home page
 ESC Textbook of Cardiovascular MedicineHome page
S. Hoeks and D. Poldermans
CHAPTER 34 Non-cardiac Surgery in Cardiac Patients
ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
A. A. Mazumder and G. A. Pope
A case of right sided weakness
BMJ, November 26, 2008; 337(nov26_2): a2427 - a2427.
[Full Text]

Home page
 Eur Heart JHome page
R. Nieuwlaat, M. H. Prins, J.-Y. Le Heuzey, P. E. Vardas, E. Aliot, M. Santini, S. M. Cobbe, J. W.M.G. Widdershoven, L. H. Baur, S. Levy, et al.
Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on Atrial Fibrillation
Eur. Heart J., May 1, 2008; 29(9): 1181 - 1189.
[Abstract] [Full Text] [PDF]

Home page
 EuropaceHome page
B. Johansson, B. Houltz, E. Berglin, G. Brandrup-Wognsen, T. Karlsson, and N. Edvardsson
Short-term sinus rhythm predicts long-term sinus rhythm and clinical improvement after intraoperative ablation of atrial fibrillation
Europace, May 1, 2008; 10(5): 610 - 617.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
R. Nieuwlaat, T. Dinh, S. B. Olsson, A. J. Camm, A. Capucci, R. G. Tieleman, G. Y.H. Lip, H. J.G.M. Crijns, and on behalf of the Euro Heart Survey Investigators
Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation?
Eur. Heart J., April 1, 2008; 29(7): 915 - 922.
[Abstract] [Full Text] [PDF]

Home page
 Occup Med (Lond)Home page
Z. Taimur and S. Hussaini
Atrial fibrillation in a commercial diver
Occup. Med., March 1, 2008; 58(2): 144 - 146.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
K Gjesdal, J Feyzi, and S B Olsson
Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data
Heart, February 1, 2008; 94(2): 191 - 196.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
F. Onorati, A. Esposito, G. Messina, A. di Virgilio, and A. Renzulli
Right Isthmus Ablation Reduces Supraventricular Arrhythmias After Surgery for Chronic Atrial Fibrillation
Ann. Thorac. Surg., January 1, 2008; 85(1): 39 - 48.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
N. Echahidi, D. Mohty, P. Pibarot, J.-P. Despres, G. O'Hara, J. Champagne, F. Philippon, P. Daleau, P. Voisine, and P. Mathieu
Obesity and Metabolic Syndrome Are Independent Risk Factors for Atrial Fibrillation After Coronary Artery Bypass Graft Surgery
Circulation, September 11, 2007; 116(11_suppl): I-213 - I-219.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
S. Habara, K. Dote, M. Kato, S. Sasaki, K. Goto, H. Takemoto, D. Hasegawa, and O. Matsuda
Prediction of left atrial appendage thrombi in non-valvular atrial fibrillation
Eur. Heart J., September 2, 2007; 28(18): 2217 - 2222.
[Abstract] [Full Text] [PDF]

Home page
 EuropaceHome page
D. N. Tziakas, G. K. Chalikias, N. Papanas, D. A. Stakos, S. V. Chatzikyriakou, and E. Maltezos
Circulating levels of collagen type I degradation marker depend on the type of atrial fibrillation
Europace, August 1, 2007; 9(8): 589 - 596.
[Abstract] [Full Text] [PDF]

Home page
 EuropaceHome page
C. Varounis, N. Dagres, T. Maounis, D. Panagiotakos, and D. V. Cokkinos
Atrial premature complexes and heart rate have prognostic significance in 1-month atrial fibrillation recurrence after electrical cardioversion
Europace, August 1, 2007; 9(8): 633 - 637.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
A. K Nergardh, M. Rosenqvist, R. Nordlander, and M. Frick
Maintenance of sinus rhythm with metoprolol CR initiated before cardioversion and repeated cardioversion of atrial fibrillation: a randomized double-blind placebo-controlled study
Eur. Heart J., June 1, 2007; 28(11): 1351 - 1357.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
P. Wierup, H. Liden, B. Johansson, M. Nilsson, N. Edvardsson, and E. W.-O. Berglin
Health Care Consumption Due to Atrial Fibrillation is Markedly Reduced by Maze III Surgery
Ann. Thorac. Surg., May 1, 2007; 83(5): 1713 - 1716.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
L. Friberg and on behalf of the SCAF study group
Stroke prophylaxis in patients with atrial fibrillation: what can we do about it?: reply
Eur. Heart J., May 1, 2007; 28(9): 1173 - 1173.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
F. Perez-Gomez, J. A. Iriarte, J. Zumalde, J. Berjon, A. Salvador, E. Alegria, M. P. Maluenda, S. Asenjo, R. Perez-Saldana, R. G. de la Torre, et al.
Antithrombotic therapy in elderly patients with atrial fibrillation: effects and bleeding complications: a stratified analysis of the NASPEAF randomized trial
Eur. Heart J., April 2, 2007; 28(8): 996 - 1003.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
L. R. Zebis, T. D. Christensen, H. F. Thomsen, M. M. Mikkelsen, L. Folkersen, H. T. Sorensen, and V. E. Hjortdal
Practical Regimen for Amiodarone Use in Preventing Postoperative Atrial Fibrillation
Ann. Thorac. Surg., April 1, 2007; 83(4): 1326 - 1331.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
F. Onorati, M. Bilotta, F. Borrello, M. Vatrano, A. di Virgilio, M. C. Comi, F. Perticone, and A. Renzulli
Successful radiofrequency ablation determines atrio-ventricular remodelling and improves systo-diastolic function at tissue Doppler-imaging
Eur. J. Cardiothorac. Surg., March 1, 2007; 31(3): 414 - 422.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
H. D. White, M. Gruber, J. Feyzi, S. Kaatz, H.-F. Tse, S. Husted, and G. W. Albers
Comparison of Outcomes Among Patients Randomized to Warfarin Therapy According to Anticoagulant Control: Results From SPORTIF III and V
Arch Intern Med, February 12, 2007; 167(3): 239 - 245.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
N. Dagres, R. Nieuwlaat, P. E. Vardas, D. Andresen, S. Levy, S. Cobbe, D. Th. Kremastinos, G. Breithardt, D. V. Cokkinos, and H. J.G.M. Crijns
Gender-Related Differences in Presentation, Treatment, and Outcome of Patients With Atrial Fibrillation in Europe: A Report From the Euro Heart Survey on Atrial Fibrillation
J. Am. Coll. Cardiol., February 6, 2007; 49(5): 572 - 577.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
A. Bobbio, D. Caporale, E. Internullo, L. Ampollini, S. Bettati, E. Rossini, P. Carbognani, and M. Rusca
Postoperative outcome of patients undergoing lung resection presenting with new-onset atrial fibrillation managed by amiodarone or diltiazem
Eur. J. Cardiothorac. Surg., January 1, 2007; 31(1): 70 - 74.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
C J Mann, S Kendall, G Y H Lip, and on behalf of the Guideline Development Group for t
Acute management of atrial fibrillation with acute haemodynamic instability and in the postoperative setting
Heart, January 1, 2007; 93(1): 45 - 47.
[Full Text] [PDF]

Home page
 HeartHome page
G Y H Lip and M Rudolf
The new NICE guideline on atrial fibrillation management
Heart, January 1, 2007; 93(1): 23 - 23.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
R. Nieuwlaat, A. Capucci, G. Y.H. Lip, S. B. Olsson, M. H. Prins, F. H. Nieman, J. Lopez-Sendon, P. E. Vardas, E. Aliot, M. Santini, et al.
Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation
Eur. Heart J., December 2, 2006; 27(24): 3018 - 3026.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
V. Badhwar, J. D. Rovin, G. Davenport, J. C. Pruitt, R. R. Lazzara, G. Ebra, and G. H. Dworkin
Left Atrial Reduction Enhances Outcomes of Modified Maze Procedure for Permanent Atrial Fibrillation During Concomitant Mitral Surgery
Ann. Thorac. Surg., November 1, 2006; 82(5): 1758 - 1764.
[Abstract] [Full Text] [PDF]

Home page
 EuropaceHome page
Writing Committee Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al.
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Europace, September 1, 2006; 8(9): 651 - 745.
[Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
M. S. Nieminen
Key issues of European Society of Cardiology guidelines on acute heart failure
Eur. Heart J. Suppl., September 1, 2006; 8(suppl_E): E6 - E11.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
A Nergardh and M Frick
Perceived heart rhythm in relation to ECG findings after direct current cardioversion of atrial fibrillation
Heart, September 1, 2006; 92(9): 1244 - 1247.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
J. Am. Coll. Cardiol., August 15, 2006; 48(4): e149 - e246.
[Full Text] [PDF]

Home page
 CirculationHome page
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Circulation, August 15, 2006; 114(7): e257 - e354.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
L. Friberg, N. Hammar, M. Ringh, H. Pettersson, and M. Rosenqvist
Stroke prophylaxis in atrial fibrillation: who gets it and who does not?: Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study)
Eur. Heart J., August 2, 2006; 27(16): 1954 - 1964.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
A. M. Gillinov, S. Bhavani, E. H. Blackstone, J. Rajeswaran, L. G. Svensson, J. L. Navia, B.G. Pettersson, J. F. Sabik III, N. G. Smedira, T. Mihaljevic, et al.
Surgery for Permanent Atrial Fibrillation: Impact of Patient Factors and Lesion Set
Ann. Thorac. Surg., August 1, 2006; 82(2): 502 - 514.
[Abstract] [Full Text] [PDF]

Home page
 EuropaceHome page
M. Strandberg, M.J. P. Raatikainen, M. Niemela, M. Luotolahti, J. Hartiala, and K.E. J. Airaksinen
Clinical practicality and predictive value of transoesophageal echocardiography in early cardioversion of atrial fibrillation
Europace, June 1, 2006; 8(6): 408 - 412.
[Abstract] [Full Text] [PDF]

Home page
 VASC ENDOVASCULAR SURGHome page
P. S. Mullenix, M. J. Martin, S. R. Steele, G. S. Lavenson Jr, B. W. Starnes, N. C. Hadro, R. P. Peterson, and C. A. Andersen
Rapid High-Volume Population Screening for Three Major Risk Factors of Future Stroke: Phase I Results
Vascular and Endovascular Surgery, May 1, 2006; 40(3): 177 - 187.
[Abstract] [PDF]

Home page
 Ann. Thorac. Surg.Home page
C. A. Rogers, G. D. Angelini, L. A. Culliford, R. Capoun, and R. Ascione
Coronary surgery in patients with preexisting chronic atrial fibrillation: early and midterm clinical outcome.
Ann. Thorac. Surg., May 1, 2006; 81(5): 1676 - 1682.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
P Korantzopoulos, T M Kolettis, A Papathanasiou, K K Naka, P Kolios, I Leontaridis, A Draganigos, C S Katsouras, and J A Goudevenos
Propafenone added to ibutilide increases conversion rates of persistent atrial fibrillation
Heart, May 1, 2006; 92(5): 631 - 634.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
F. Perez-Gomez, A. Salvador, J. Zumalde, J. A. Iriarte, J. Berjon, E. Alegria, C. Almeria, R. Bover, D. Herrera, C. Fernandez, et al.
Effect of antithrombotic therapy in patients with mitral stenosis and atrial fibrillation: a sub-analysis of NASPEAF randomized trial
Eur. Heart J., April 2, 2006; 27(8): 960 - 967.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
J. Tenczer and J. Tomcsanyi
Classification of atrial fibrillation
Eur. Heart J., March 1, 2006; 27(5): 621 - 621.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
D. G. Wyse
Classification of atrial fibrillation: reply
Eur. Heart J., March 1, 2006; 27(5): 621 - 622.
[Full Text] [PDF]

Home page
 EuropaceHome page
D. Schwartzman, M. N. Harvey, R. H. Hoyt, J. L. Koehler, M. R. Ujhelyi, and D. E. Euler
Utility of adjunctive single oral bolus propafenone therapy in patients with atrial defibrillators.
Europace, March 1, 2006; 8(3): 211 - 215.
[Abstract] [Full Text] [PDF]

Home page
 EuropaceHome page
A. Vincenti, R. Brambilla, M. G. Fumagalli, R. Merola, and S. Pedretti
Onset mechanism of paroxysmal atrial fibrillation detected by ambulatory Holter monitoring.
Europace, March 1, 2006; 8(3): 204 - 210.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
G. Stabile, E. Bertaglia, G. Senatore, A. De Simone, F. Zoppo, G. Donnici, P. Turco, P. Pascotto, M. Fazzari, and D. F. Vitale
Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study)
Eur. Heart J., January 2, 2006; 27(2): 216 - 221.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
A. M. Gillinov, F. Bakaeen, P. M. McCarthy, E. H. Blackstone, J. Rajeswaran, G. Pettersson, J. F. Sabik III, F. Najam, K. M. Hill, L. G. Svensson, et al.
Surgery for Paroxysmal Atrial Fibrillation in the Setting of Mitral Valve Disease: A Role for Pulmonary Vein Isolation?
Ann. Thorac. Surg., January 1, 2006; 81(1): 19 - 28.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
A. M. Gillinov, J. Sirak, E. H. Blackstone, P. M. McCarthy, J. Rajeswaran, G. Pettersson, F. J. Sabik III, L. G. Svensson, J. L. Navia, D. M. Cosgrove, et al.
The Cox maze procedure in mitral valve disease: Predictors of recurrent atrial fibrillation
J. Thorac. Cardiovasc. Surg., December 1, 2005; 130(6): 1653 - 1660.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
R. Nieuwlaat, A. Capucci, A. J. Camm, S. B. Olsson, D. Andresen, D. W. Davies, S. Cobbe, G. Breithardt, J.-Y. Le Heuzey, M. H. Prins, et al.
Atrial fibrillation management: a prospective survey in ESC Member Countries: The Euro Heart Survey on Atrial Fibrillation
Eur. Heart J., November 2, 2005; 26(22): 2422 - 2434.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
D. G. Wyse
The Euro Heart Survey on atrial fibrillation: a picture and a thousand words
Eur. Heart J., November 2, 2005; 26(22): 2356 - 2357.
[Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
E. E. Roselli, S. C. Murthy, T. W. Rice, P. L. Houghtaling, C. D. Pierce, D. P. Karchmer, and E. H. Blackstone
Atrial fibrillation complicating lung cancer resection
J. Thorac. Cardiovasc. Surg., August 1, 2005; 130(2): 438 - 444.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
V Tuseth, H J Jaatun, and K Dickstein
Amiodarone infusion in the treatment of acute atrial fibrillation or flutter: high versus low dose treatment
Heart, July 1, 2005; 91(7): 964 - 965.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
S. J. Walsh, D. McCarty, A. J.J. McClelland, C. G. Owens, T. G. Trouton, M. T. Harbinson, S. O'Mullan, A. McAllister, B. M. McClements, M. Stevenson, et al.
Impedance compensated biphasic waveforms for transthoracic cardioversion of atrial fibrillation: a multi-centre comparison of antero-apical and antero-posterior pad positions
Eur. Heart J., July 1, 2005; 26(13): 1298 - 1302.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
P. Kirchhof, G. Monnig, K. Wasmer, A. Heinecke, G. Breithardt, L. Eckardt, and D. Bocker
A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA)
Eur. Heart J., July 1, 2005; 26(13): 1292 - 1297.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
M. Duytschaever, Y. Blaauw, and M. Allessie
Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs
Cardiovasc Res, July 1, 2005; 67(1): 69 - 76.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
A. M. Gillinov, P. M. McCarthy, E. H. Blackstone, J. Rajeswaran, G. Pettersson, J. F. Sabik III, L. G. Svensson, D. M. Cosgrove, K. M. Hill, G. V. Gonzalez-Stawinski, et al.
Surgical ablation of atrial fibrillation with bipolar radiofrequency as the primary modality
J. Thorac. Cardiovasc. Surg., June 1, 2005; 129(6): 1322 - 1329.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
G. Fayad, T. Le Tourneau, T. Modine, R. Azzaoui, P.-V. Ennezat, C. Decoene, G. Deklunder, and H. Warembourg
Endocardial Radiofrequency Ablation During Mitral Valve Surgery: Effect on Cardiac Rhythm, Atrial Size, and Function
Ann. Thorac. Surg., May 1, 2005; 79(5): 1505 - 1511.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
K. Bando, H. Kasegawa, Y. Okada, J. Kobayashi, A. Kada, T. Shimokawa, M. Nasu, S. Nakatani, K. Niwaya, O. Tagusari, et al.
Impact of preoperative and postoperative atrial fibrillation on outcome after mitral valvuloplasty for nonischemic mitral regurgitation
J. Thorac. Cardiovasc. Surg., May 1, 2005; 129(5): 1032 - 1040.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
M. O'Donnell, G. Agnelli, and J. I. Weitz
Emerging therapies for stroke prevention in atrial fibrillation
Eur. Heart J. Suppl., May 1, 2005; 7(suppl_C): C19 - C27.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
J. Emmerich, J.-Y. Le Heuzey, P. M.W. Bath, and S. J. Connolly
Indication for antithrombotic therapy for atrial fibrillation: reconciling the guidelines with clinical practice
Eur. Heart J. Suppl., May 1, 2005; 7(suppl_C): C28 - C33.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
P. S.J. Miller, M. F. Drummond, L. K. Langkilde, J. J.V. McMurray, and M. Ogren
Economic factors associated with antithrombotic treatments for stroke prevention in patients with atrial fibrillation
Eur. Heart J. Suppl., May 1, 2005; 7(suppl_C): C41 - C54.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
M. Lehto, S. Snapinn, K. Dickstein, K. Swedberg, M. S. Nieminen, and on behalf of the OPTIMAAL investigators
Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience
Eur. Heart J., February 2, 2005; 26(4): 350 - 356.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
Endorsed by the European Society of Intensive Care, Authors/Task Force Members, M. S. Nieminen, M. Bohm, M. R. Cowie, H. Drexler, G. S. Filippatos, G. Jondeau, Y. Hasin, J. Lopez-Sendon, et al.
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology
Eur. Heart J., February 2, 2005; 26(4): 384 - 416.
[Full Text] [PDF]

Home page
 BMJHome page
M B. Iqbal, A. K Taneja, G. Y H Lip, and M. Flather
Recent developments in atrial fibrillation
BMJ, January 29, 2005; 330(7485): 238 - 243.
[Full Text] [PDF]

Home page
 EuropaceHome page
M. F. Scholten, A. S. Thornton, J. M. Mekel, P. J. Koudstaal, and L. J. Jordaens
Anticoagulation in atrial fibrillation and flutter
Europace, January 1, 2005; 7(5): 492 - 499.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
A A J Adgey and S J Walsh
Theory and practice of defibrillation: (1) Atrial fibrillation and DC conversion
Heart, December 1, 2004; 90(12): 1493 - 1498.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
F. Perez-Gomez, E. Alegria, J. Berjon, J. A. Iriarte, J. Zumalde, A. Salvador, L. Mataix, and NASPEAF Investigators
Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: A randomized multicenter study
J. Am. Coll. Cardiol., October 19, 2004; 44(8): 1557 - 1566.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
M P Currie, S P Karwatowski, J Perera, and E J Langford
Introduction of nurse led DC cardioversion service in day surgery unit: prospective audit
BMJ, October 16, 2004; 329(7471): 892 - 894.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
F Marin, V Roldan, V E Climent, A Ibanez, A Garcia, P Marco, F Sogorb, and G Y H Lip
Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation
Heart, October 1, 2004; 90(10): 1162 - 1166.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
G. D. Veenhuyzen, C. S. Simpson, and H. Abdollah
Atrial fibrillation
Can. Med. Assoc. J., September 28, 2004; 171(7): 755 - 760.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
N. van Hemel
Quinidine rehabilitated and more lessons from the PAFAC and SOPAT anti-arrhythmic drug trials for the prevention of paroxysmal atrial fibrillation
Eur. Heart J., August 2, 2004; 25(16): 1371 - 1373.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
T. Fetsch, P. Bauer, R. Engberding, H. P. Koch, J. Lukl, T. Meinertz, M. Oeff, L. Seipel, H. J. Trappe, N. Treese, et al.
Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial
Eur. Heart J., August 2, 2004; 25(16): 1385 - 1394.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
F. Lombardi, D. Tarricone, F. Tundo, F. Colombo, S. Belletti, and C. Fiorentini
Autonomic nervous system and paroxysmal atrial fibrillation: a study based on the analysis of RR interval changes before, during and after paroxysmal atrial fibrillation
Eur. Heart J., July 2, 2004; 25(14): 1242 - 1248.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
G. Troise, M. Cirillo, F. Brunelli, G. Tasca, A. Amaducci, Z. Mhagna, M. Dalla Tomba, and E. Quaini
Mid-term results of cardiac autotransplantation as method to treat permanent atrial fibrillation and mitral disease
Eur. J. Cardiothorac. Surg., June 1, 2004; 25(6): 1025 - 1031.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
C-J A Lindholm, O Fredholm, S-J Moller, N Edvardsson, T Kronvall, T Pettersson, V Firsovaite, A Roijer, C J Meurling, P G Platonov, et al.
Sinus rhythm maintenance following DC cardioversion of atrial fibrillation is not improved by temporary precardioversion treatment with oral verapamil
Heart, May 1, 2004; 90(5): 534 - 538.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. P. Mathew, M. L. Fontes, I. C. Tudor, J. Ramsay, P. Duke, C. D. Mazer, P. G. Barash, P. H. Hsu, and D. T. Mangano
A Multicenter Risk Index for Atrial Fibrillation After Cardiac Surgery
JAMA, April 14, 2004; 291(14): 1720 - 1729.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Sports. Med.Home page
G Whyte, N Stephens, S Sharma, R Shave, R Budgett, and W J McKenna
Spontaneous atrial fibrillation in a freestyle skier
Br. J. Sports Med., April 1, 2004; 38(2): 230 - 232.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
C. Bode
Recent trials in atrial fibrillation: lessons learned beyond rate and rhythm
Eur. Heart J. Suppl., April 1, 2004; 6(suppl_B): B15 - B19.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
B.A. Schaer, M.J. Zellweger, T.A. Cron, C.A. Kaiser, and S. Osswald
Value of Routine Holter Monitoring for the Detection of Paroxysmal Atrial Fibrillation in Patients With Cerebral Ischemic Events
Stroke, March 1, 2004; 35 (3): e68 - e70.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
B. J. Maron, W. J. McKenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn, C. E. Seidman, P. M. Shah, W. H. Spencer III, P. Spirito, F. J. Ten Cate, et al.
American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines
J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1687 - 1713.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
Writing Committee Members, B. J. Maron, W. J. McKenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn, C. E. Seidman, P. M. Shah, W. H. Spencer III, P. Spirito, et al.
American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines
Eur. Heart J., November 1, 2003; 24(21): 1965 - 1991.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
Committee Members, C. Blomstrom-Lundqvist, M. M. Scheinman, E. M. Aliot, J. S. Alpert, H. Calkins, A. J. Camm, W. B. Campbell, D. E. Haines, K. H. Kuck, et al.
ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias --executive summary: a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) Developed in Collaboration with NASPE-Heart Rhythm Society
J. Am. Coll. Cardiol., October 15, 2003; 42(8): 1493 - 1531.
[Full Text] [PDF]

Home page
 CirculationHome page
C. Blomstrom-Lundqvist, M. M. Scheinman, E. M. Aliot, J. S. Alpert, H. Calkins, A. J. Camm, W. B. Campbell, D. E. Haines, K. H. Kuck, B. B. Lerman, et al.
ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias*--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias)
Circulation, October 14, 2003; 108(15): 1871 - 1909.
[Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
A. Schuetz, C.J. Schulze, K.K. Sarvanakis, H. Mair, H. Plazer, E. Kilger, B. Reichart, and S.M. Wildhirt
Surgical treatment of permanent atrial fibrillation using microwave energy ablation: a prospective randomized clinical trial
Eur. J. Cardiothorac. Surg., October 1, 2003; 24(4): 475 - 480.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
G. Gronefeld, J.R. Ehrlich, and S.H. Hohnloser
Comparison of outpatient vs inpatient direct current cardioversion of atrial fibrillation: safety, efficacy and cost savings
Eur. Heart J. Suppl., September 1, 2003; 5(suppl_H): H19 - H24.
[Abstract] [PDF]

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?